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The human placenta is a gender-specific, interim endocrine organ that grows in the uterus 
during pregnancy, with the placenta attaching the evolving fetus to the uterine wall through the 
umbilical cord to supply oxygen and nutrients. The placenta is also responsible for facilitating 
removal of waste products and carbon dioxide from the fetus, and with protecting the fetus from 
infectious agents and foreign substances that can be introduced across the placental barrier. Until 
the revelation of thalidomide-induced birth defects in the late 1960s, the human placenta was 
assumed to be an impenetrable barrier shielding the fetus from xenobiotics transfused from the 
maternal bloodstream. Thereafter, the placenta became a very contentious subject within the 
scientific community and the pharmaceutical industry because of concerns related to uncertainty 
associated with usage of xenobiotics and prescribed drugs during pregnancy. Many in vivo, ex 
vivo, and in vitro models and platforms for conducting placental drug screening have been 
developed by researchers, but despite these numerous attempts, a lack of physiological functions 
exhibited by those models and platforms have restricted the modeling of realistic human-placenta 
responses for conducting accurate drug-transport studies. This dissertation aims to present a 
microfluidic platform that has been developed to mimic structural phenotypes and physiological 
characteristics of a human placenta that can be used to simulate near-transport studies of 
xenobiotics and pharmaceutical drugs across the human placenta.   
 The usage of pregnant animal subjects has been a previously-preferred method for in vivo 
experimentation, but ex vivo experimentation has mostly been conducted on perfusion models of 
human placentas derived from post-delivery. Because of differences between humans and animals 
with respect to physiological characteristics of placentation, current in vivo drug transport studies 
of the human placenta have mostly produced erratic outcomes and the ex vivo perfusion models 
xvi 
used lack representation of physiological characteristics over the course of pregnancy. Chapter 2 
highlights how the placenta-on-a-chip, a micro-engineered device fabricated utilizing microfluidic 
technology, has revolutionized the processes of overcoming many issues previously experienced 
for both in vivo and ex vivo models.   
 Following fabrication and verification of the placenta-on-a-chip, it was initially used to 
study caffeine transport across the placental barrier in vitro. Caffeine, primarily found in natural 
sources such as coffee, tea, and cocoa, is one of the most widely-consumed psychoactive drugs in 
the world. Because of absence of enzymes responsible for metabolizing caffeine in the fetal liver, 
concerns have been raised that a high maternal caffeine intake might harm the fetus. Chapter 3 
presents a study conducted to quantify fetal caffeine concentration and rate of caffeine transfer 
from a continuous maternal perfusion of 0.25 mg mL-1 over a span of 7.5 h. There is limited 
information about the safety of using naltrexone (NTX), a common form of medication, prescribed 
for treating opioid addiction during pregnancy, and concerns have been raised about the effects of 
this drug on the fetus and its brain. Chapter 4 is a near-transport study of NTX and its major 
metabolite, 6β-naltrexol, across the placental barrier to the fetus and its brain. 
 While the placenta-on-a-chip device and associated transport studies summarized in the 
following chapters suggest this device as a possible in vitro placental drug-testing platform, further 
studies are required to achieve a sufficiently accurate model for the pharmaceutical industry to use 
in performing placental drug transport studies.   





CHAPTER 1.    GENERAL INTRODUCTION 
1.1. Motivation 
The human placenta is a vital organ that performs as the liver, lungs, kidneys, gut, and 
endocrine glands of the fetus during pregnancy.[1] Women are known to consume various 
xenobiotics and pharmaceutical drugs during pregnancy due to a long-term habit or medical 
condition. Most xenobiotics and pharmaceutical drugs cross the placental barrier unless they are 
either completely metabolized in the liver of the mother or the molecular size and lipid solubility 
of the compound restricts the placental passage.[2] Fetal-exposure to drugs can result in fetal 
implications at the stage of fetal development and after birth. Despite the fact that most mothers 
consume some form of xenobiotic and/or pharmaceutical drug during pregnancy, very little is 
known about the amount that crosses the maternal-fetal interface.  
In recent years, an extensive number of in vivo, ex vivo, and in vitro studies have been 
performed to study the drugs-transport across the human placenta. Outcomes from these studies 
have tended to provide inconsistent conclusions due to the difference between the models 
developed and the real-human placentas. Most animal-based in vivo experimentation has involved 
structural and physiological differences in the placenta, while ex vivo studies have replicated only 
a certain period of the placentation. With the development of in vitro studies, researchers have 
been encouraged to develop drug-testing platforms that can mimic the physiological and structural 
functions of human organs, including the human placenta. One in vitro model that has gained the 
attention of researchers is the use of organs-on-chips technology. This research provides a proof-
of-concept of a drug-testing platform that utilizes organs-on-chips technology, which it then uses 
this to model the drug-transport across the human placenta. 
2 
1.2. Research Objectives 
The objective of the studies presented in this dissertation is to develop an in vitro model of 
the human placenta utilizing microfluidics and organs-on-chips technology. The microfluidic 
device should present the structural phenotypes and physiological characteristics of a human 
placenta. Once this device is confirmed as providing a near-representation of the human placenta 
in vitro, it will be used to perform near-transport studies of xenobiotics and pharmaceutical drugs. 
Caffeine is used to simulate xenobiotic transport, while naltrexone and its primary metabolite, 6β-
naltrexol, is used as the pharmaceutical drug transport.  
 
1.3. Outline 
The following chapters may be summarized thus: 
Chapter 2: A literature review of the recent in vivo, ex vivo, and in vitro studies is presented, and 
how the placenta-on-a-chip revolutionizes placental drug transport studies is 
discussed; 
Chapter 3: A study performed to quantify fetal caffeine concentrations and rate of transfers is 
presented; 
Chapter 4: Fetal exposure to naltrexone and its major metabolite, 6β-naltrexol, is studied and a 
prototype for fetal-brain exposure during a similar exposure is presented; 
Chapter 5: General conclusions of the research and recommendations for future work are 
described.  
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Abstract 
In the past few decades, the placenta became a very controversial topic that has had many 
researchers and pharmacists discussing the significance of the effects of pharmaceutical drug 
intake and how it is a possible leading cause towards birth defects. The creation of an in vitro 
microengineered model of the placenta can be used to replicate the interactions between the mother 
and fetus, specifically pharmaceutical drug intake reactions. As the field of nanotechnology 
significantly continues growing, nanotechnology will become more apparent in the study of 
medicine and other scientific disciplines, specifically microengineering applications. This review 
is based on past and current research that compares the feasibility and testing of the placenta-on-
a-chip microengineered model to the previous and underdeveloped in vivo and ex vivo approaches. 
The testing of the practicality and effectiveness of the in vitro, in vivo, and ex vivo models requires 
the experimentation of prominent pharmaceutical drugs that most mothers consume during 
pregnancy. In this case, these drugs need to be studied and tested more often. However, there are 
challenges associated with the in vitro, in vivo, and ex vivo processes when developing a practical 
placental model, which are discussed in further detail.  
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2.1. Introduction 
The human placenta is an extremely critical and complicated organ that performs a variety 
of functions. Those functions are comprised of a few of the following: ensuring the safety and 
security of fluid, nutrient, and oxygen circulation and flow; the removal of waste products and 
carbon dioxide; and the shielding from harmful diseases, infections, and xenobiotics from the 
mother to fetus. The performance of these actions supports the development and maturity of the 
fetus.[1-4] The structure of the placenta is composed of a placental trophoblast and fetal capillary 
endothelium layer. The two cell layers separate the fetal circulation from the maternal blood, 
ensuring that no intermingling occurs between the two blood flows.[5] Unfortunately, studying and 
monitoring the placenta is very difficult, considering the structure of the placenta goes through a 
considerable amount of alterations during pregnancy.[6] Not to mention, as pregnancies increase 
within mothers, more dramatic alterations begin taking place in their placental barrier, making the 
testing and monitoring even more challenging.[6]  Although the placenta is very difficult to examine 
and study, the knowledge that humans are gaining from the placenta proves to be a vital source for 
humanity's understanding of the human placenta’s overall behavior and system. Therefore, the 
functionalities and structure of the placenta play a vital role in the testing, surveillance, and 
understanding of the placental barrier’s properties and purpose in the human body. Understanding 
the physiology behind the placenta creates a foundation for researchers to pave a model, for the 
scientific community and pharmaceutical industry, towards the testing and better understanding of 
the human placenta. 
Until these past couple of decades, there was an idea circulating around researchers, 
pharmacists and the public that the placenta is an impenetrable barrier that does not impose any 
fatal or severe effects upon the mother or fetus.[7] However, the discovery of thalidomide-induced 
birth defects in the late 1960s dismantled that argument.[7] A few years after the discovery of the 
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thalidomide-induced birth defects, Boston University's Slone Epidemiology Center Birth Defects 
Study (BDS) began conducting an array of detailed interviews with a diverse selection of pregnant 
women, which still takes place annually.[8] The intent of this program is to survey the medication 
that pregnant women are taking throughout the duration of their pregnancy. When the data is 
collected, researchers analyze the trend of medication intake by pregnant women and compare the 
intake towards the rise, causes and formation of birth defects. The collection of this data supports 
the proposed argument by researchers around the globe that pregnant women are taking 
medications more frequently and these medications need to be studied more thoroughly. The 
pharmaceutical industry is also faced with a considerable amount of complaints and concerns, 
surrounding their integrity and the safety of their drugs and adequacy.[9] To bring statistics into the 
argument, statistics display the fact that approximately 45.3% out of every pregnant woman uses 
prescription medicine, excluding vitamins.[10] As the growth and skepticism of pharmaceutical and 
over-the-counter drugs become more popular for pregnant women, the testing of the feasibility 
and effectiveness of these drugs needs to be taken more seriously in order to prevent these 
increasing measures in birth defects. For example, the development and utilization of the in vivo 
systems, and ex vivo and in vitro devices has helped scientists to study the effects and harms that 
these drugs are imposing on the human placenta. 
A variety of in vivo systems, and ex vivo and in vitro devices have been developed, for the 
most part, to mimic and replicate the metabolism process and active transport in the human 
placenta.[7, 11] The development of the placenta-on-a-chip and other in vivo and ex vivo systems 
avoids the risk of the rupturing and disturbance of the fetus and mother.[12-14] The use of these 
instruments creates a more viable and systematic approach towards the testing and understanding 
the effects that pharmaceutical and other medicated drugs inflict upon the placenta. However, 
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scientists have become increasingly more interested in the placenta-on-a-chip model for testing, 
especially in the past few years. While the in vivo and ex vivo systems do recapitulate a few of the 
behaviors and functions performed by the human placenta, they struggle with the resources and 
technology to carry out these tests effectively. Nonetheless, these approaches are being 
overshadowed by the growing desire and promise that the in vitro model possess. With growing 
interest and development in the field of nanotechnology, the placenta is being infused into 
nanomedical related applications, particularly on-a-chip utilization.[7, 15]  The microengineered 
placenta-on-a-chip is the face of a new generation of technology that is becoming ever more so 
demanding in the study of the placenta. Although there are numerous amounts of challenges 
involved in the in vitro models, the models’ abilities can be used to replicate the effects that 
pharmaceutical drugs are inflicting on the placental barrier. Most importantly, though, applying 
the placenta-on-a-chip to the study and understanding of the placenta will give rise towards the 
clarification on how pharmaceutical drugs and other diseases are leading causes of birth defects 
and mutations in the mother’s placental barrier. 
 
2.2. Human Placenta 
The placenta (Figure 2.1) serves as a vital organ in the production and growth of the fetus. 
The placenta performs as the kidneys, lungs, gut, and liver throughout the duration of pregnancy 
in order to keep the fetus alive.[16-17] Based on the physiology of the placenta, the placental barrier 
is structurally defined by the placental trophoblast and fetal capillary endothelium layer, because 
they are the foundation and building blocks towards the development of other components of the 
placental barrier.[5] The combination of the placental trophoblast and endothelium layer support 
the development of the chorionic villi. Throughout most of the pregnancy, the placenta’s chorionic 
villi serve as the main structural component of the placental barrier, which is composed primarily  
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Figure 2. 1. Human placenta. (a) Fetus in developing stages attached to an umbilical cord and uterine wall. 
(b) Cross-sectional view of the placenta. (c) Detailed diagram of the cross-sectional view of villus that 
reveals the placental barrier’s intervillous space, villous endothelial cells, and syncytiotrophoblast. 
Reproduced with permission from [5]. Copyright © 2016 RSC.  
of cytotrophoblasts. Cytotrophoblasts are the inner layer of the trophoblast and the stem cells for 
the syncytiotrophoblast. The main roles the syncytiotrophoblast plays into the development of the 
placenta is the synthesization of progesterone and estrogens, and the operation of the endocrine 
unit. Along with the synthesization and operation of estrogens, progesterone, and endocrine, the 
syncytiotrophoblast plays a significant role in the production of the placental growth hormone and 
peptide hormone.[18] To take into consideration, the separation between the cytotrophoblast and 
the syncytiotrophoblast is largely dependent on the syncytiotrophoblast; the syncytiotrophoblast 
covers each villus after being compressed into a layer that separates the lucanue from the 
cytotrophoblast layer. Furthermore, the separation of the two layers creates intervillous spaces that 
ensure the growth of the fetus.[19] In the course of the developments and processes carried out by 
the cytotrophoblasts and syncytiotrophoblast, their actions occur throughout the beginning portion 
of pregnancy, when the fetal organ development occurs in an environment with low oxygen 
pressure.[16] Scientists need to acquire a great deal of knowledge regarding the physiology behind 
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the placental barrier in order to mimic the functionalities of the human placenta for pharmaceutical 
and other experimental purposes. 
Understanding the solute across the placenta is critical when examining the placental 
barrier mechanisms. The migration of solute across the placental barrier, for the most part, begins 
in the later developments of the fetus when the structural components of the placental barrier are 
able to withstand the diffusion of fluids. In order for fetal growth to perform efficiently, the 
exchange of products and nutrients across the placenta is essential. Scientists still struggle to fully 
understand the inner mechanisms towards the exchange of fetal metabolism over the placental 
barrier. However, scientists have been able to discover and formulate a significant amount of 
information that gives researchers a general idea of the inner mechanisms of the placental barrier. 
In large part, the concentration gradient of the substance, extent, and thickness of the placental 
barrier are needed for the performance of the transfer of nutrients.[18-19] The paracellular 
permeability and electrical potential difference are both major factors that come into play when 
studying the solute exchange across the placenta. Another significant mechanism towards the 
transferring of nutrients across the placenta are the functions that the transporter protein carries 
out: transporting glucose, hydrophobic molecules, and amino acids across the placenta. In fact, 
transporter proteins are located in the plasma membrane along with carriers, which are membrane 
proteins as well. The purpose of the carriers is to merge themselves with the solute and transport 
the solute to other parts of the membrane, similarly to the transporter proteins.[20-21]  The 
functionalities and system of exchange of fluids across the placental barrier is an important part of 
the placenta. In order for researchers to replicate the human placenta for experimental purposes, 
they must take the diffusion across the placental barrier and the complex physiology of the placenta 
into consideration when developing the most practical model possible.   
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2.3. In Vivo  
The in vivo model for testing is an underdeveloped approach towards the study and testing 
of pharmaceuticals for the better understanding of the human placenta.[22] One of the most common 
and extended methods of testing is the experimentation on animal subjects, especially for medical-
related purposes. The use of pregnant animals is a favored in vivo model for testing and studying 
the functionalities and pharmaceutical effects of medicated drugs across the placenta.[23]  Rodents 
and mammals, like rats [24-26], rabbits [27-28] , camels [29-31], and pigs [32-34] have all served as previous 
subjects for an in vivo model towards the replication of the functionalities and structure of the 
human placenta. Nonetheless, animal models vary dramatically from human physiology, making 
data comparisons difficult to match from an animal to a human placenta.[35] Although scientists 
have utilized a variety of animal placentas for pharmaceuticals testing, the mouse and sheep 
placenta are the two in vivo subjects that will be discussed in further detail. The sheep and mouse 
placenta models are chosen for discussion for two particular reasons. One, the mouse and sheep 
model have proven to be popular approaches towards the evaluation and transability of using their 
placentas in place of human placentas for pharmaceutical testing, which is evident from the 
upcoming table and explained in the upcoming sections. Secondly and most importantly, though, 
the mouse model has a paracellular and extracellular route of exchange similarly with the human 
placenta,[36] and the fetal-placental vascular structure in the sheep model shares more resemblances 
with the human placenta than the majority of other mammals.[14] Similar physiological 
characteristics between the mouse, sheep and human placenta make for more effective assessments 
and support for the in vivo’s background in pharmaceutical and functional analysis evaluations.  
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2.3.1. Mouse and Sheep Model 
 
Figure 2. 2. Compares and contrasts the physiology between the human, mouse, and sheep placentas. (a1-
a3) Section views that reveal the human placenta and embryo, uterine-trophoblast interface, and blood-
trophoblast interface. (b1-b3) Section views that reveal the mouse placenta and embryo, uterine-trophoblast 
interface, and blood-trophoblast interface. (c1-c3) Section views that reveal the sheep placenta and embryo, 
uterine-trophoblast interface, and blood-trophoblast interface. Reproduced with permission from [37]. 
Copyright © 2012, Elsevier. 
Researchers of the past and present are still fixated on the idea of testing on animals, 
believing that genetically mutated animals, particularly the mouse (Figure 2.2b1-b3), can be used 
to replicate the human placenta (Figure 2.2a1-a3). The mouse is one of the most important, if not 
the best, subjects for in vivo testing of the placenta. The reason is that the mouse placental barrier 
has one of the closest structures to the human placenta due to the correspondents of both of their 
designs being a haemochorial type.[36] The use of mouse trophoblast is also an alternative solution 
for the difficulty in obtaining primary human tissue, because researchers can efficiently use 
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trophoblast stem cells to mimic the features of the human syncytiotrophoblasts.[38] In addition to 
the resembling physiological traits between the two placentas, the mouse and human placenta both 
have a similar diffusion coefficient of water and allowance of inert hydrophilic solutes. Similar 
placental physiological exchange between the human and mouse placenta has played a vital role 
in the development and progression of the mouse model.[36] Not to mention, for most scientists, 
time is a valuable factor when carrying out experiments and analysis, in which nominates mice a 
leading candidate for experimentation. The reason is that mice are particularly easy to breed and 
handle, due to their high reproductive rate and rapid development.[39]  Overall, though, scientists 
have acquired a considerable amount of information regarding the comparable biological and 
genetic characteristics between the mouse and human placenta in the past few decades, supporting 
the argument that the mouse model is an appropriate model for study.[36]  
While the mouse placenta does provide a comparative advantage over other rodents and 
mammals when testing the effects of medicated drugs on the placenta, scientists have spent a 
considerable amount of time evaluating the feasibility of the sheep placenta (Figure 2.2c1-c3) for 
future pharmaceutical testing. The reason is that researchers have achieved an extensive amount 
of progress modifying and assessing the sheep placenta for medical and analytical related 
purposes. For instance, the nutrient metabolism and respiration of the mammalian fetus are a 
couple of examples of the knowledge humans have gained from studying pregnant sheep.[40] 
Scientists have also taken advantage of the sheep placenta when testing and exploring the maternal-
fetal structure and interactions when developing an in vivo model to examine placental nutrient 
transfer.[40] To mention however, sheep, for the most part, have researchers surgically perform on 
their placenta when the fetus has reached a substantial weight and the maturity is quite high. In 
contrast though, the mouse model usually has the scientists genetically modify the mouse placenta 
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and operate the surgical procedures earlier in the fetal development.[41] Nevertheless, the previous 
testing for nutrient metabolism and placental nutrient transfer on the sheep placenta, was only 
made possible due to the shared physiological traits between the sheep and human placenta. Since 
the sheep and human placenta share alike biological qualities, scientists have been able to conduct 
and translate medicated-drug related testing from the sheep to the human placenta. Corresponding 
physiological characteristics can be found in the villous tree of the sheep cotyledon, which shares 
a similar structure with the villous tree of the human placenta. Additionally, both the sheep and 
human placentas are structurally divided up into cotyledons and share alike fetal placental vascular 
structures.[42]  Nonetheless, scientists have acquired a significant volume of knowledge regarding 
the feasibility and structure of the sheep model for in vivo pharmaceutical testing, making the 
following approach a candidate for study. To summarize, as researchers continue taking advantage 
of the mouse and sheep approaches, scientists will grasp a fuller understanding on how they can 
manipulate and apply these models towards the better understanding on how medicated-drugs 
affect the human placenta. 
 
2.3.2. Studies Concerning the Mouse and Sheep Model 
Since the mouse and sheep model are studied quite frequently among scientists, researchers 
have been able to conduct a variety of experiments across the mouse and sheep placentas. Table 
2.1 presents an array of experiments pertaining towards the utilization and application of the mouse 
and sheep models towards the study and evaluation of pharmaceuticals and functional analysis on 
their placentas. More specifically, Table 2.1 categorizes each work by species, type of testing, 
details regarding experimentation, and conclusions from the analysis. 
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Species Type of 
testing 
Details Conclusions Ref. 
Mouse Toxicity/Drug 
Testing 
Test the effects that lithium, 
homocysteine, and alcohol 
in mouse placenta 
The mouse placenta can 
prevent intrauterine growth 
retardation (IUGR) caused by 
lithium, homocysteine, and 
alcohol 
[43] 
  Evaluated the effects 
progesterone on Breast 
Cancer Resistance Protein 
(BCRP) in mouse placenta 
in vivo   
Increased levels of 
progesterone did not have any 
noticeable effects on BCRP 
[44] 
  Tested for thalidomide-
induced limb irregularities 
in humanized cytochrome 
P450 3A (CYP3A) mouse 
model in vivo 
Limb abnormalities were 
recorded, human CYP3A was 
showed in mouse placenta, 
concluding that mouse model 
can predict toxicity in humans 
[45] 
  Analyze effects that anti-
oxidant Tempol has on 
mouse model during fetal 
growth in vivo 
Tempol improved the fetal 
growth in mouse placenta, 
and increase in the velocity of 




Use gestation in trophoblast 
of a mouse placenta to study 




GAPDH may have multiple 
purposes in trophoblast cells 
[47] 
  Evaluated venous 
morphological, functional, 
and arterial differences in 
the mouse fetoplacental 
vascular network 
Fetoplacental veins and 
arteries differ between their 
branching scaling rules, and 
fetoplacental resistance is 
made up 26% of veins 
[48] 
  Evaluate Interleukin-(IL)11 
in mouse placenta, and IL1β 
and TNFα their effects on 
placental villous explants  
IL11 turned out to be 
regulated by pro-
inflammatory cytokines IL1β, 







Table 2.1 Continued 
Species Type of 
testing 
Details Conclusions Ref. 
  Examined human placental 
mesenchymal stromal cells 
(PMSC) in a mouse model 
in vivo 
PMSC had positive effects on 
neovascularization in mouse 
model in vivo 
[50] 
  Characterized lymphocyte 




is expressed from LY6E and 
may be found in progenitors  
[51] 
  Studied parasite dynamics in 
mouse placental labyrinth 
layer using intravital 
microscopy 
infected-Red Blood Cells 
(iRBCs) can be internalized 
by trophoblast cells, and 
quick removal of particles 
inside blood flow is a 
characteristic of placental 
blood flow  
[52] 
  Evaluate Cited2’s effects on 
vascularization and 
trophoblast formation on 
mouse placenta in vivo  
Normal placental 
vascularization and 
development requires Cited2 
to promote embryo growth  
[53] 
  Examined how 
transcriptional co-repressor 
TLE3 promotes 
development if giant 
trophoblast cells in mouse 
placenta  
Growth and differentiation of 
trophoblast giant cells is 
regulated by TLE3, and TLE3 
have placenta deficiencies  
[54] 
  Tested Argonaute 2 (AGO2) 
effects on differentiation 
mouse Embryonic stem cells 
in vivo  
Extra-embryonic endoderm 
genes need AGO2, and AGO2 
plays a significant role in 
stem cell differentiation  
[55] 
  Evaluated the Breast Cancer 
Resistance Protein (BCRP) 
in mouse placenta in vivo   
Mouse placenta expressed the 
fact that BCRP limits the 
effects of medicated-drugs 









Table 2.1 Continued 
Species Type of 
testing 
Details Conclusions Ref. 
  Studied the transfer of 
maternal cholesterol in 
mouse in vivo  
The transfer of maternal 
cholesterol was evident in the 
mouse, and the yolk and 
placenta are the sites for 




Evaluated triclosan in sheep 
placenta 
Triclosan is a potent inhibitor 
of sulfotransferase in the 
sheep placenta, and reduces 
the total placental estrogen 
secretion  
[57] 
  Examine the uptake of 
transdermal fentanyl in 
pregnant sheep 
The fentanyl transfer rate was 
77%, and recorded low pain 
scores after laparotomy and 
hysterotomy 
[58] 
  Analyze the rosiglitazone in 
the sheep plasma and the 
effects rosiglitazone has on 
pregnant sheep in vivo 
Study proves to be ideal for 
pharmacokinetic studies in 
sheep model, and successfully 
applied the determination of 





Tested for the enhancement 
of the cytokine expression 
from maternal obesity (MO) 
in sheep placenta    
MO increased the placental 
inflammatory responses of 
kappa-light-chain-enhancer of 
activated B cells (NF-κB) and 




  Test the effects that human 
Amnion Epithelial cells 
(hAEC) have on sheep acute 
inflammatory response in 
vivo 
hAEC does not significantly 
alter the acute fetal 






Table 2.1 portrays an array of studies towards the evaluation of medicated-drugs, toxins 
and the functional analysis of the mouse placental barrier in vivo. As illustrated, researchers have 
been able to test a few medicated drugs like Tempol [46], progesterone [44], thalidomide [45] across 
the mouse placenta, and mimic a substantial quantity of the human placental features. More 
importantly, the collection of these data results on the mouse model proves to be vital when 
Table 2.1 Continued 
Species Type of 
testing 
Details Conclusions Ref. 
  Examined the impact that 
chronic maternal stress 
(CMS) has on fetal stress 
sensitivity and maternal-
fetal stress transfer in sheep 
placenta  
CMS promotes maternal-fetal 
stress transfer, and increases 
fetal hypothalamus–pituitary–
adrenal (HPA) responsiveness  
[61] 
  Evaluate the effects that 
hypoxemia has on fetal 
ventricular deformation in 
sheep in vivo  
Fetal cardiac function in 
altered ventricular demoration 
is changed substantially due 
to hypoxemia 
[62] 
  Measure the effects of 
genotype and nutrient on 
Prion Protein (PrPC) gene in 
sheep placenta 
Genotype affects PrPC but 
not the protein expression 
levels 
[63] 
  Analyze carbohydrate 
metabolism in sheep 
placenta in vivo 
Glucose may form fructose 
though sorbitol in placental 
cells 
[64] 
  Use sheep placenta to 
evaluate electron 
microscopy of the 
localization of ferric iron in 
vivo 
Ferric iron was observed in 
the epithelial cytoplasmic 
matrix, and liberated from 
digested hemoglobin  
[65] 
  Evaluated caspase 
mechanisms of apoptosis 
across sheep model in vivo   
When apoptosis-inducing 
factor (AIF) and telomerase 
activity (TA) are increased, 
apoptotic mechanisms do not 
require caspase signaling  
[66] 
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comparing the results towards previous data from the effects of these medicated drugs have on the 
human placenta.[39] Fortunately, results in correlation with the effects that Tempol, progesterone, 
and thalidomide have on fetal growth and glucose metabolism showed evident similarities towards 
the natural reactive effects they impose on the human placental barrier. To acknowledge, however, 
Tempol, progesterone, and thalidomide are popular medications that most pregnant women 
consider throughout their pregnancy and require to be studied more often for behavioral 
interactions with the fetus. Nonetheless, if it was not for the mouse alternative tissue in place for 
human tissue, the imitation of Tempol, progesterone, and thalidomide across the placenta would 
not be as efficiently carried out as with other rodents and mammals.[38] In addition to medicated-
drug testing on the mouse placenta, there is an immense amount of evaluating pertaining towards 
the functional analysis and inner structure of the mouse placenta, retaining towards the transability 
of using the mouse placenta in place of the human placenta for pharmaceutical testing. For 
example, scientists tested mesenchymal stromal cells [50], maternal cholesterol [56], proteins [44], 
and other characteristics across the mouse placenta in order to decide if the mouse placenta shares 
comparable biological characteristics with the human placenta. Based on data and conclusions of 
Table 2.1, researchers found that the mouse placenta shares similar protein and cellular features 
with the human placental barrier. Thus, the mouse placenta may be an appropriate model for 
medicated-drug testing in the near future, because of the shared qualities in physiological features 
and medicated-drug reactions with the human placenta. 
 While the mouse placenta has had a substantial amount of testing performed across the 
model’s placenta, the sheep approach has proven to have a solid record of accomplishment of 
assessing as well. Ever since researchers have been taking advantage of the sheep placenta, they 
have been able to evaluate the inner mechanisms of the sheep placental barrier, and the effects that 
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triclosan [57], rosiglitazone [22], and transdermal fentanyl [58]  have on fetal growth and glucose 
metabolism. Based from Table 2.1, there has been a substantial amount of accomplishments 
pertaining towards the evaluation of the functional analysis and inner mechanisms of the sheep 
placental barrier in vivo. Similarly, with the mouse model, from fluid transfer to membrane and 
protein examinations, the sheep model has been a reliable method for the study and transability of 
the model’s functional analysis for the better understanding of the human placenta. Nonetheless, 
there have also been a few medicated tests performed across the sheep placental barrier. Those 
tests pertain towards the evaluation of triclosan, transdermal fentanyl, and rosiglitazone have on 
the sheep placenta. To make notice, triclosan, transdermal fentanyl, and rosiglitazone are common 
medications that women take during pregnancy and have a modest volume of information on their 
implications on fetal growth. Nevertheless, the medicated-drug testing conclusions from Table 2.1 
revealed whether the sheep placenta is an alternative and suitable approach for medicated-drug 
testing in place of the human placenta. Fortunately, results in correlation with the effects that 
triclosan, transdermal fentanyl, rosiglitazone have on fetal growth and glucose metabolism 
demonstrated evident resemblances towards the normal reactive effects they impose on the human 
placental barrier based from the conclusions of their research in Table 2.1. Therefore, the sheep 
placenta may also be an appropriate model for pharmaceutical experimentation in the upcoming 
future, considering the human placenta’s similar qualities in medicated-drug reactions and 
physiological features. Moreover, given the fact that scientist have executed a countless amount 
of functional analysis tests and a few pharmaceutical evaluations on the sheep and mouse models, 
supports the argument that both models have the potential to be alternative approaches for studying 
the human placenta in vivo. 
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2.3.3. Mouse Model Limitations  
 
Figure 2.3. Compares the physiology between the human and mouse placenta. (a) Section-views of the 
mouse and human placenta that reveal the similarities and differences between the generic physiologies of 
the two placentas. (b) Detailed views of the mouse and human placenta that compare and contrast the 
microscopic physiological characteristics of the two placentas. Reproduced with permission from [67]. 
Copyright © 2013, Elsevier.  
Despite the mouse advantages as serving as an in vivo model for testing, the mouse placenta 
has only partially been able to prove the vitally of being an essential source for studying the effects 
of several medicated drugs across the placenta. The association towards the invalidity of the mouse 
placenta serving as a model for replicating the human placenta is because the physiology of the 
mouse placenta distinguishes itself quite substantially from the human placenta. The structure of 
the mouse placenta compares differently to the human placenta due to the mouse placenta 
consisting of labyrinthine and junctional zones (Figure 2.3). Another reason why the physiology 
behind the mouse and human placenta differentiate is because the mouse placenta consists of a 
three-layered trophoblast (haemotrichorial) while the human placenta consists of a single 
syncytiotrophoblast zone and layered trophoblast (haemomonochorial).[36, 39, 68] In addition to the 
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physiological trait variances between the two placentas, scientists are still struggling to replicate 
the alveolar growth and expansion in the mouse placenta, based on their own prototype 
alveologenesis. Not to mention, there is still no clear explanation why researchers cannot develop 
an intact basal membrane that can organize itself into the correct human placental tissue.[39] 
Contrasting physiology and the inability for scientists to duplicate the biological qualities between 
the mouse and human placenta are contributing factors towards comparison error and irrelevant 
data. In this case, the results from the tests will have limited valuable data for any success in 
creating a stable method for the testing of pharmaceutical drugs across the placenta. In order for 
the in vivo model to become completely practical, the model must recapitulate the functionalities 
and physiology of a human placenta in almost every way possible, ensuring that the model can be 
vital towards the testing of pharmaceutical drugs.  
Since scientists are struggling to find a solution that diminishes the contrasting 
physiological barriers between the mouse and human placenta, researchers have been unable to 
develop a concrete or practical procedure that can carry on any significant medicated-drug tests.[36] 
For example, even though scientists have evaluated Tempol, progesterone and thalidomide on the 
mouse placenta, researchers have been unable to perform a broad range of pharmaceuticals across 
the mouse placental barrier. For instance, the testing of diabetic or human immunodeficiency virus 
(HIV) medication — two commonly prescribed medicated-drugs to pregnant women — across the 
mouse placenta should be taking place more often by now, considering that scientists have been 
working on the in vivo mouse model for decades.[69-70] Besides all the pessimism that surrounds 
the mouse model, researchers have successfully devoted the majority of their time trying to modify 
these mice to mimic human functionalities (Table 2.1), but should consider assessing the effects 
of pharmaceutical drugs on the mouse placenta more frequently.  
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2.3.4. Sheep Model Limitations   
While there has been a substantial quantity of testing accomplished on the sheep placenta, 
the model is an underdeveloped approach towards the testing of medicated-drugs on the sheep 
placental barrier. One reason, particularly, is the fact that the physiological structure and glucose 
transfer between the sheep and human placenta distinguishes from each other quite substantially. 
For example, sheep have specialized territories of well vascularized, while the human placenta has 
a conceptus that invades into the uterine wall. Sheep also have a considerable amount of individual 
attachment sites composed of the maternal caruncle and fetal cotyledon; however, the human 
placenta has a large discoid placenta. In addition to the differences in physiological traits between 
the two placentas, glucose transporter proteins, GLUT-1 and GLUT-3, are developed and regulated 
in the sheep placenta but not in the human placenta. Not to mention, GLUT-1 is limited to the base 
of the syncytial layer of the sheep placenta, but localized in the vascular endothelial cells of the 
human placenta. This variation in placental structure and glucose transfer gives most scientists less 
motivation to carry out this method, because of the raised concerns in the invalidity of the sheep 
placenta serving as a model for replicating the human placenta.[42]  
Let alone, although there has been success towards the testing of mineral traces, maternal-
fetal structure and interactions, and transdermal fentanyl and triclosan in the sheep placenta 
approach, scientists have executed a modest number of pharmaceutical tests on the sheep placenta. 
Researchers have been spending the majority of their time testing the feasibility of the sheep 
placenta model in order to prove that their models will produce the same natural reactions from 
pharmaceutical intake that occurs in the human placenta. In order for the sheep model to become 
fully practical, the model first must be able to completely replicate the physiology and 
functionalities of the human placenta.[42] If not, then the tests will have no significance towards 
the comparison of data from the performance of pharmaceutical analyses on the sheep placenta to 
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the human placenta. Fortunately, scientists have been testing and ensuring that the sheep model 
imitates the similar physiological functionalities with the human placenta (Table 2.1), even though 
the structure between the two placentas differentiate from each other significantly. Nonetheless, 
researchers could consider the testing of more pharmaceuticals across the sheep placenta in the 
upcoming years to ensure that there is a balance between functional analysis and pharmaceutical 
experimentation on the sheep placenta. Furthermore, the in vivo model of the sheep placenta is in 
the development stages of replicating the physiology of the human placental barrier, which has 
been limiting the potential testing of medicated-drugs on the model’s placenta. 
 
2.3.5. Future of In Vivo Model Development   
Although the practicality of the in vivo model for the testing of pharmaceutical drugs on 
the placenta has been tested in many unique and complicated ways, the use of animals for clinical 
and experimental trials is facing an extensive loss in support and disappreciation, due to the 
model’s invalidity of transability towards human study.[71-72] The use of animals for the testing of 
pharmaceuticals is considered doubtful due to the difference in placentation between humans and 
other animals. Rodents and mammals also lack the surplus quantity of trophoblast in the villous 
structure within the myometrium and endometrium of the placenta. Moreover, financial and ethical 
constraints, from testing on animals, tend to play a critical role in the lack of resources and 
motivation for researchers to run trials and experiments on the placenta.[73-74]   
The leading reason why researchers are still analyzing this method for studying the human 
placenta is that drug responses can be predicted and tested most accurately in vivo.[71] Nevertheless, 
the replacement for the use of the in vivo approach for testing and examining the human placenta 
will be largely due to the progress and improvement on the placenta-on-a-chip.[35] The in vivo 
method is the most primitive methods for studying the placenta, and as explained before, the in 
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vivo model has not obtained a significant amount of progress in tested pharmaceuticals. In large 
fault, though, scientists are still in the development stages of the mouse, sheep, and other animal 
models, in which the models are still being improved upon in order for more pharmaceutical testing 
to take place.[22] Nonetheless, although the in vivo approach has seen a substantial amount of 
progress throughout the past couple of decades, the in vivo method lacks current resources and 
knowledge to carry out an effective universal procedure for in vivo model consisting of mice, 
sheep, and other animals. The testing of animal subjects may seem prominent for other medicated 
applications; however, because of the complexity of the placenta, the existence of a developed in 
vivo method for testing the durability and validity of pharmaceutical drugs could potentially lose 
support in the near future. To ensure the continuation and support for the in vivo approach, 
scientists could consider the testing of more pharmaceuticals on their animal models in the 
upcoming future.  
 
2.4. Ex Vivo 
The utilization of the ex vivo approach has been witnessing a decline in the scientists’ 
ability to develop a practical perfusion model that can test pharmaceuticals on real human placenta 
tissue. For clarification, ex vivo means the testing on a live organism is done outside of the host, 
while in vivo and in vitro studies are conducted in the living host and cultured system, 
respectively.[35] The ex vivo model serves as possibly one of the most frequently tested, but 
complicated procedures when engaging in the testing of pharmaceutical drug intake of the 
placenta. However, most scientists prefer this model over the in vivo method towards the study of 
recapitulating the features of the human placenta.[35] The reason is that in the fetal and maternal 
umbilical plasma of a human, calculating the course of a drug is nearly impossible in vivo; 
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however, the ex vivo has proven to be successful to calculate the course of a drug.[75] Nevertheless, 
likewise with the in vivo method for replicating the human placental barrier, the ex vivo model of 
testing is found most frequently in mature placental subjects.[76]   
While the ex vivo and in vivo approaches share several similarities and differences, the 
perfusion model itself has a range of advantages towards the study of the human placenta. A few 
of the primary benefits of the human placental perfusion is that the model offers information about 
placental storage, metabolism, transplacental transfer and vascularization.[35] Another benefit of 
the ex vivo model is the fact that the approach does not cause severe damage to the maternal 
vasculature due to being torn from the uterine wall. The cause of interindividual fluctuation in the 
transplacental transfer is an additional benefit that has also been characterized by the ex vivo 
perfusion model.[77-78] The most essential factor when considering the applicability of the ex vivo 
model is the representation of real human tissue, due to the fact, that real human tissue plays a vital 
role in the performance of perfusion experimental studies.[77-79] The representation of real human 
tissue is the justification for why researchers have frequently been using and improving this 
method, in which their experiments will include the natural reactions that the placenta releases in 
vivo during pharmaceutical drug intake. 
 
2.4.1 Ex vivo Perfusion Model 
The following models are a human placental perfusion system (Figure 2.4a) and dual 
placenta perfusion model (Figure 2.4b1 and b2) from Malek et al. [80] and Conings et al. [81], 
respectively, who adopted the first ex vivo perfusion model developed by Panigel et al. [82] and 
later modified by Schneider et al. [83], Myllynen et al. [84], Mathiesen et al. [12, 85], Myren et al. [35], 
and others research groups. Circulating (Figure 2.4) and non-recirculating perfusion are the two  
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Figure 2.4. Ex vivo perfusion model. (a) The depicted diagram represents a human placenta perfusion 
system for testing perfusion across human placental tissue with specifics retaining towards the materials 
and set-up of the perfusion model. Reproduced with permission from [80]. Copyright © 2003, Elsevier. 
(b1,b2) A constructed ex vivo perfusion model that shows the labelled experimental set-up. Reproduced 
with permission from [81]. Copyright © 2017, Elsevier. 
most prominent types of ex vivo placental perfusion systems. Yet, the circulating model has proved 
to be the suitable approach when testing perfusion across the placental barrier.[77-78] For example, 
the procedure carried out by Myllynen et al.[79] for the experimentation of the ex vivo model to test 
antipyrine concentration was a major success in reconstructing the placental perfusion model. 
Since Myllynen et al. have had a substantial amount of success pertaining towards the utilization 
of their perfusion model, the construction of their perfusion model can be used as an example for 
the development of an ex vivo placental perfusion.[79] Or, the following studies listed in the next 
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section can be investigated for further information on the construction of an ex vivo placental 
perfusion.  
 
2.4.2. Studies Concerning Ex Vivo Perfusion Model 
Considering the fact that the ex vivo perfusion model is studied quite frequently among 
scientists, researchers have been able to conduct a variety of experiments in ex vivo. Table 2.2 
presents an array of experiments pertaining towards the utilization and application of the ex vivo 
perfusion model towards the examination and evaluation of pharmaceuticals, toxins and the inner 
mechanisms of the placental barrier in ex vivo. More specifically, Table 2.2 categorizes each work 
by type of testing, details regarding the study, and conclusions from analysis.  





Details Conclusions Ref. 
Toxicity/Drug 
Testing 
Testing for antipyrine 
concentrations in ex vivo  
Results revealed that the antipyrine 
concentrations of both the maternal 
and fetal concentrations ended up 
equal, revealing the success of a 
circulating perfusion model and the 
model’s placental transfer 
[79] 
 
Examined the fetal drug 
compartment concentrations 
by exposing the placental-
trophoblastic barrier with a 
variety of carboplatin 
concentrations 
Revealed that fetal kidney cells are 
affected by the carboplatin and 
efficiently mimicked carboplatin in 
real human tissue. 
[86] 
 
Determined the extent and rate 
of maternal-fetal 
transplacental passage of 
bromocriptine (BCT) in ex 
vivo  
Concluded that only trace amounts of 
BCT could transport across the 






Table 2.2 Continued  
Type of 
testing 
Details Conclusions Ref. 
 
Use the ex vivo for 
testing the placental 
transfer of maraviroc 
Proved to be successful and relatable to the in vivo 
model, due to the accurate ratios in the maternal 
blood samples and umbilical cord 
[88] 
 
Test placental transfer of 
rosiglitazone in 
perfusion model 
Discovered that rosiglitazone passes through the 
placenta at a low rate, and there is minimal fetal 




Measure the transfer of 
lamivudine across the 
human placenta in ex 
vivo 
By simple diffusion, lamivudine appears to 
passover the placenta 
[90] 
 
Measure the transfer of 
lamivudine across the 
human placenta with 
zidovudine 
Appearance of lamivudine is not altered by the 
presence of zidovudine in the placenta 
[90] 
 
Tested placental transfer 
of enfuvirtide in 
perfusion model 
Enfuvirtide placental transfer was not detected or 
observed, concluding that enfuvirtide can be used 
in human immunodeficiency virus (HIV)-infected 





fetal transfer of 
granisetron in ex vivo 
perfusion model  
Granisetron has concentration dependent placental 
transfer, and at systemic granisetron 




Test the human placental 
transfer of hydralazine in 
ex vivo perfusion model 
Hydralazine crosses the ex vivo perfusion model 
readily, and that the absorption of hydralazine in 
the fetal compartment was in linear relationship 





metformin across the 
placenta using ex vivo  
Metformin displayed a higher transport rate from 
the fetal-maternal side, and is mediated by a 






Table 2.2 Continued 
Type of 
testing 
Details Conclusions Ref. 
 
Tested the maternal-fetal 
transfer of saquinavir in 
perfusion model 
Low rates of placental transfer of 
saquinavir were calculated, revealing that 
the use of this drug will possibly not be 
exposed significantly to the fetus 
[95] 
 
Analyzed the placental 
transfer of pioglitazone and 
sitagliptin in ex vivo  
Significant fetal accumulation of 
pioglitazone, clearance indexes, and 
extended half-life of pioglitazone and 
sitagliptin are not tolerable for treating 
diabetes during pregnancy 
[96] 
 
Evaluated the transplacental 
transfer of oseltamivir using 
ex vivo perfusion model  
The transplacental transfer of oseltamivir 
phosphate was detected significantly, 






oxygenation levels in ex vivo  
Heterogeneity was displayed through 
intervillous space (IVS) oxygen mapping, 
and discovered that whole placental 
lobules displated 3D placental 
oxygenation maps at great resolution 
[98] 
 
Analyzed the feto-placental 
vasculature of the placenta 
using perfusion model  
Ex vivo model can efficiently evaluate the 
dependency of Doppler ultrasound 
clinical measures for placental 
obstruction   
[99] 
 
Examined the transportation 
of immunoglobulin G (IgG) 
in ex vivo 
The human placenta develops a specific 
transport mechanism for IgG for the fetal 
and maternal direction 
[100] 
 
Examined the transportation 
IgG subclasses in ex vivo    
Transfer rates for all four classes varied. 
IgG1 had the preferential transfer, while 
IgG2 had the slowest transfer 
[100] 
 
Evaluated the differences of 
placental elasticity between 
normal and IUGR 
pregnancies using perfusion 
model 
IUGR group displayed more 
histopathological changes and were 
stiffer than the control group, and that 
reduced placental elasticity could be the 





Most of the following tests summarized in Table 2.2 use the circulating placental diffusion 
model for all experimental analysis, and carry out the perfusion assembly as mentioned in the 
previous section. However, there are perfusion composition differences between the experiments, 
which are not necessarily accounted for. Furthermore, previous ex vivo studies have proven to be 
beneficial when studying the causes and effects that certain pharmaceutical drugs have on the 
transplacental passage.[75] Many of the pharmaceutical drugs relate towards anti-epileptic drugs 
and HIV protease inhibitors, which have been tested on the ex vivo model since the mid-1990s.36 
As well as the testing and validating of anti-epileptic drugs and HIV protease inhibitors, the ex 
vivo model has been used to study and test the transplacental passage of exogenous and 
endogenous compounds and the examination of the transfer of amino acids in the placenta.[75, 103] 
Additionally, the replication of the effects of diseases like cancer and other drugs have been used 
as a model for assessing the effectiveness of the placental perfusion.[86] Placental perfusion based 
on Table 2.2, and the ex vivo model in general, has proven to successfully replicate carboplatin in 
the human tissue, evaluate the maternal drug transfer across preterm birth, and analyze the 
functional components of the placental barrier on human placental tissue. In these cases, the ex 
vivo perfusion model has successfully analyzed for the reactive behavior released from the human 
placental tissue, and provided scientists accurate understandings on how glucose transfer and 
placental elasticity affect fetal growth. In addition, researchers have been able to use this 
Table 2.2 Continued 
Type of 
testing 
Details Conclusions Ref. 
 
Examined the maternal 
transfer of Interleukin-6 in the 
ex vivo perfusion model 
Minimal maternal to fetal transfer of 
Interleukin-6 was observed from the ex 
vivo perfusion model 
 [102] 
30 
knowledge to attain new understandings on how these drugs affect the human placenta, and what 
can be done to ensure that these drugs do not impose any harm on the mother and fetus. Thus, what 
can be concluded from the success of the ex vivo model is that the placental perfusion process has 
not been a misfortune in the model’s development.  
 
2.4.3. Future of Ex Vivo Model Development   
The ex vivo model may present many significant contributions towards the study of the 
placenta and the effects that pharmaceutical drugs impose on the placental barrier; however, the 
ex vivo approach does not have a standardized placental perfusion method, due to the difference 
in perfused compositions.[75] Unfortunately, the ex vivo model does not weigh placental transfer 
across the entire pregnancy, and cannot necessarily recapitulate the binding to serum proteins in 
vivo conditions such as rilpivirine, a compound used to study placental transfer.[104] The potential 
of the ex vivo placental perfusion model has limitations, such as having a laborious placental 
perfusion set-up procedure and cannot handle the broad scale of chemical testing and screening.[79] 
Not to mention, the ex vivo model does not last long, because of the model’s short lasting 
performance and output of experimental results.[73] Currently, the model can last approximately 
from 2-4 hr to 6-8 hr for short and long experiments, respectively.[35] Comparatively, in vitro 
studies do not include the usage of real human tissue, allowing experiments to last for days on end 
usage.  
Although one could argue that the practicality of the ex vivo model has proven to be more 
sustainable than the in vivo approach, the perfusion model does not show the same compatibility 
as the placenta-on-a-chip. Likewise, with the in vivo sheep and mouse model, the perfusion model 
does not necessarily have a concrete model that can test the effects that medicated drugs and other 
diseases can impose upon in the placental barrier. To argue rather, the perfusion model has gained 
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significantly more progress in medicated-drug testing than the in vivo approach and has had more 
success with the model’s experiments dealing with the replication of antipyrine, placental transfer 
of maraviroc, and maternal drug transfer across preterm birth. Support for this claim can be found 
and exemplified in the variances in quantities of medicated-drug testing between Table 2.1 and 
Table 2.2. Nevertheless, the model has limitations and is arguably a difficult procedure to carry 
out effectively due to the short-lasting performance of the model, time composition, inability to 
handle a considerable amount of chemicals, and other constraints. In order for the ex vivo model 
to not see a decline in the support in the placental perfusions continuation to run tests for 
pharmaceutical effects across the placenta tissue, scientists should consider developing a fully 
practical and universal model that diminishes the differences between perfused compositions and 
other limitations. In large fault though, the ex vivo approach will likely see a decline in the support 




2.5.1. Microfluidic Devices 
The placenta-on-a-chip model (Figure 2.5) is the closest to the completion of a practical 
model that can replicate the physiology and functionality of the human placenta for the testing and 
transability of pharmaceutical intake from an in vitro model to an in vivo human placenta. 
Microfluidic devices serve as the foundation and system for the testing and analysis of 
pharmaceuticals in the in vitro model. The development of the distinct physical setting of the 
microfluidic devices enables the ability for researchers to culture and manage the cellular and 
subcellular environments, and maintain a definite arrangement of the cells.[106-107] Microfluidic  
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Figure 2.5. (a) An image of the inner structure of the microfluidic device that includes the 
poly(dimethylsiloxane) (PDMS) microchannels. (b) The physical setting of a common placenta-on-a-chip. 
The maternal (red) and fetal (blue) microchannels are separated by a vitrified collagen (VC) membrane in 
the center of the chip.[105] Scale bar, 1 cm. Reproduced with permission from Miura et al. [105] / CC BY 
systems additionally allow researchers to gather the most significant amount of data in the shortest 
period of time, reduce sample utilization, and mimic the flow of fluids in parallel layers.[108-113] A 
large portion of the microfluidic device’s abilities were developed and managed by a handful of 
research groups, Sadao et al.[114], Matsunaga et al.[115], Takinoue et al.[116], Kiriya et al.[117], Onone 
et al.[118] and Kazayama et al.[119], who have spent the past decade developing and modifying the 
microfluidic devices for drug, cellular, and tissue analytical simulation studies. Moreover, many 
of these advantages are influenced by the chip’s capability to structurally withstand the co-
culturing of endothelial and trophoblast cells. 
An important component of the microfluidic device, and the in vitro model in general, is 
that the placenta-on-a-chip requires the representation of endothelium and trophoblastic epithelium 
in order for the replication of the fetal and maternal interfaces of the placenta. When the 
endothelium and trophoblastic epithelium in the human placenta are represented accurately, the in 
vitro model can perform a variety of tests that replicate the physiology of the placental barrier, and 
the circulation of pharmaceutical intake and diseases between the mother and fetus. The growth 
factors, cytokines, hormones, nutrients, intercellular junctions, and extracellular matrices are all 
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additional examples of soluble and insoluble aspects that can be mimicked through the use of a 
microengineered co-culture model of a placenta-on-a-chip.[72]  
Data and tests have also proven well for the microfluidic devices, and have opened the 
doors to a realm of organs-on-chips[120] : bone-on-a-chip[121], liver-on-a-chip[122], body-on-a-
chip[123], kidney-on-a-chip[124], lung-on-a-chip[125], cancer-on-a-chip[126], heart-on-a-chip[127], and 
brain-on-a-chip[128]. The following organs-on-chips reveal that the on-a-chip process is used quite 
frequently in the medical industry, and is becoming ever so demanding for the better understanding 
of the human body. For example, the in vitro models have proven to successfully develop 
treatments for diabetes, leukemia, and hyper-cholesterol.[74] Nonetheless, most scientist can agree 
upon that the microengineering of the placenta-on-a-chip serves as the most practical model that 
requires the smallest budget compared to the ex vivo and in vivo, and procedure to test 
pharmaceutical intake on the in vitro model’s cultured cells and membranes. Overall, though, the 
3D cell-culture model proves to be compatible and capable of withstanding the ability to support 
tissue differentiation, cell growth, and growth factors. In this case, there has been a growing 
interest in the placenta-on-a-chip’s ability for scientists to directly manipulate human endothelial 
and trophoblast cells. 
Figure 2.6. The following microfluidic device was tested for bacterial infection. (a) The following 
schematic depicts a diagram of a cross-sectional view of the microfluidic device; a porous membrane 
separates the maternal and fetal channels in the microfluidic device. (b) The maternal and fetal sides were 
composed of BeWo cells and HUVECs, respectively. (c) Illustrating how Bacteria commonly passes 
through the placental barrier to the fetus, causing nutrients and gasses to be exchanged. [129] Copyright © 
2018 American Chemical Society. 
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The microfluidic device (Figure 2.6) serves as the primary support for the placenta-on-a-
chip and must be fabricated efficiently before cell culture, cell seeding in the chip, and analysis of 
the placental barrier can be performed.[5] Several research groups, including Miura et al.[105], Lee 
et al.[130], Blundell et al.[5, 131], Zhu et al.[129], Yin et al.[132], and Pemathilaka et al.[133], have carried 
out the previously stated procedures for their placenta-on-a-chip. In this case, the groups were able 
to successfully prepare and combine microfluidics and biology, produce confluent layers of 
endothelial and trophoblast cells within the chip’s channels, and perform experimental analyses 
on their placenta-on-a-chip. Therefore, their experimental methods will be elaborated in the next 
few sections.   
Table 2.3. Summary and comparison of placenta-on-a-chip experiments. 
 
 







Fluid shear stress (FSS) triggered microvilli 
formation in BeWo cells and human villous 
trophoblasts 
 
Exposing BeWo cells to FSS caused the 
development of a functional microvilli with 
GLUT1  
 
TRPV6 played a significant role in FSS-induced 
Ca2+ influx 
 
Calcium signaling regulated apical localization of 
Ezrin 
 
Placenta-on-a-chip can effectively replicate a 
human placental barrier microvilli surface in vitro  
 
Microfluidic device exhibits the polarized 
localization of multidrug resistance-associated 








Table 2.3 Continued 
Type of Testing Details Cultured 
Cells 
Ref. 
Glucose  Glucose was not affected by the JEG-3 cells and 
HUVECs interactions 
 
Glucose transporters discovered within the cultured 
cell lines played a critical role in glucose transfer  
 
Confluent layers of trophoblast and endothelial 
cells were determined to be present throughout the 
device  
 
Glucose crossed through the vitrified collagen 
membrane with little to no interference  
 
Placenta-on-a-chip recapitulates the characteristics 
on an in vivo human placenta when confronted with 
glucose transfer 
 
Microchip has the potential to serve as a model for 
replicating the critical components of placental 
disorders and evolving into a platform for disease 










Glucose Analyzed microvilli formation and intercellular 
junctions 
 
Trophoblast channel-mediated glucose transport  
 
Fetal channel plays an underlying role in glucose 
transfer  
 
The morphological and functional differentiation of 
BeWo cells reconstructed the syncytium of an in 
vivo human placenta  
 
Model allows for precise management of 
trophoblast and endothelial cells and microvilli to 
analyze, visualize, and replicate the human 











Table 2.3 Continued 
Type of Testing Details Cultured 
Cells 
Ref. 
 The microchip’s success has opened the doors for 
evaluating pathogens, chemicals, and drug transfer 
across the human placental barrier in vitro 
  
Glyburide/Heparin Microvilli generation on the apical side of the 
maternal channel 
 
Heparin passage was efficiently deflected from 
crossing the fetal channel 
 
BeWo cells were dominant in the administration of 
glyburide 
 
Syncytialization across the entire monolayer was 
not reachable  
 
Microfluidic device is capable of analyzing 
glyburide and heparin transport across the human 
placental barrier in vitro  
 
Model could potentially examine the alternations in 
placental tissue during pathogen, toxin, and 









Bacterial infection BeWo cells formed the desired microvilli profile 
 
GLUT1 was expressed highly in the maternal 
channel 
 
Bacterial infection stimulated the maternal 
channel’s inflammatory cytokines  
 
Bacterial infection encouraged the stimulation of 
maternal macrophages 
 
Placenta-on-a-chip can model the complicated 
inflammatory responses in human placenta in vitro 
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 mechanical cues, physiochemical factors, and other 
microenvironmental factors into the model’s 
system 
  
Nanoparticles  TiO2-NPs accumulated and transferred across the 
maternal channel 
 
The integrity of cell junction, production of 
reactive oxygen species (ROS), and adhesion of 
maternal macrophages were explored 
 
Microvilli formation in trophoblastic cells was 
examined 
 
GLUT1 was expressed in the maternal channel  
 
No dramatic alternations in ROS production were 
detected  
 
Microchip can be used as a platform to investigate 
nanoparticles in human placenta in vitro 
 
Model possesses the capability to examine food 
safety and environmental toxins in a human 









Caffeine  Cell detachment was reported to cause fluctuations 
in caffeine concentrations 
 
Semipermeable membrane integrity proved 
efficient overtime  
 
Caffeine rates warranted further investigation  
 
Caffeine absorption was identified across the edges 
of the maternal channel’s PDMS walls 
 
Placenta-on-a-chip can be used as a platform for 
investigating caffeine concentrations in human 











Through the following studies listed in Table 2.3, Miura et al.[105], Lee et al.[130], Blundell 
et al.[5, 131], Zhu et al.[129], Yin et al.[132], and Pemathilaka et al.[133] have successfully created a 
placenta-on-a-chip. The fabrication process for their microfluidic devices is a concrete and 
universal procedure method that most scientists use. The reason why is because the model allows 
researchers to compare their tests and results due to the consistency of their fabrication process. 
Since fabrication was performed adequately for all the studies, and similar culturing and seeding 
methods were used among the variety of experiments, analysis of their placental barriers produced 
satisfactory results pertaining towards the confluence of trophoblast and endothelial cells. In this 
case, their microfluidic devices were prepared for the study of glucose, glyburide, heparin, 
bacterial infection, nanoparticles and caffeine across their microengineered barriers. Moreover, the 
placenta-on-a-chip’s microengineered approach has a well-developed procedure that is being 
progressed to replicate the physiology and pharmaceutical intake of an in vivo placenta. 
 
2.6. Experiments and Analysis from Placenta-on-a-Chip 
2.6.1. Glucose 
The replication of the physiology and transfer of fluids of the human placenta in the in vitro 
model is the most crucial step towards the testing of pharmaceuticals across the placenta- 
on-a-chip because the in vitro model must completely reproduce the natural reactions that the 
human placenta releases when confronting pharmaceutical intake. The analysis and study of the  
Table 2.3 Continued 
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Figure 2.7. Glucose perfused across Blundell et al. placenta-on-a-chip. (a) GLUT1 transporters and DAPI 
staining are expressed by the color red and blue, respectively. Scale bar, 10 µm. (b) Green dots represent 
the concentration gradient of glucose crossing from the maternal to the fetal compartment. (c) Glucose rates 
from the placenta-on-a-chip, Transwell co-culture, and ex vivo perfusion studies are displayed for 
comparison. (d) A graphical representation presents percent increase in fetal glucose concentration for a 
bare membrane, trophoblast monoculture and co-culture system. Reproduced with permission from [5]. 
Copyright © 2016, RSC. 
glucose transfer across the placenta-on-a-chip barrier is a significant and logical way of studying 
the strength, reactiveness, and fluid flow of the model’s co-cultured placental barrier. Glucose 
serves as a vital factor during normal pregnancy when transporting overt and gestational diabetic 
medication on the placental barrier. Glucose is also predominantly found across the placental 
barrier.[105, 130, 134] Two examples of the testing of glucose across the in vitro model’s placental 
barrier can be found in Lee et al.[130] and Blundell et al.[5] experiments, which carried a similar 
approach for the glucose perfusion.  
Lee et al. began the testing and analyses of glucose transfer across their placenta-on-a-chip, 
by introducing glucose concentrations to the fetal and maternal sides of the chip. EGM TM-2 
containing a lower glucose concentration (1.1 g mL−1) was introduced to the endothelial channel, 
while DMEM supplemented with a higher concentration (4.5 g mL−1) of glucose was added in the 
trophoblast channel. The introduction of these glucose concentrations replicates glucose gradients 
across the placental barrier, so the in vitro membranes release a more recognizable reaction that 
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mimics the behavior of an in vivo placenta. Next, 30 μL h−1 of a continuous flow of the glucose-
supplemented culture media was maintained in the channels for 68 h. Lastly, the outlets at the end 
of the lower and upper channels were used to collect the perfused media. An evaluation of the 
lower maternal compartment’s reduction in glucose concentration was also evaluated to determine 
if gradient-induced passive diffusion or glucose transporters were responsible for fluctuations in 
glucose concentrations across the chip. Analysis from the placental cells revealed that glucose 
transporters were a significant factor towards the differences in maternal and fetal glucose 
concentrations, as well as gradient-induced passive diffusion.[130] 
Blundell et al. began the placenta-on-a-chip glucose study by perfusing the maternal 
channel with F-12K medium, supplemented with 10 mM of glucose to increase the glucose 
concentration levels generated by F-12K medium. Nonetheless, on the fetal side, the media 
contained 5.5 mM of glucose during perfusion. During the perfusion process, outflow from both 
microchannels was collected over a 2 h period. The collected flow was analyzed by a glucose 
meter, that measured glucose concentrations.[5]   
The results carried out in the testing and analysis of glucose transfer rates turned out to be 
successful and revealed metabolic consumption. Lee et al. results indicated that the final transfer 
rates of the co-culture model yielded from 17.3%-39.1%, which is approximately in the same range 
of the in vivo transfer rates.[130] Similar rates can also be compared to Blundell et al. placenta-on-
a-chip glucose transfer rates. Blundell et al. microchip produced a glucose rate of 34.8%. The 
following glucose transfer rate was found to be in the same approximately of an ex vivo glucose 
study, that produced glucose rates from 26.5%-38.3% (Figure 2.7c).[5]  Based on observation, the 
yielded glucose rates from both Lee et al. and Blundell et al. shared similar rates with an in vivo 
placenta and an ex vivo study, respectively, indicating the proficiency of both glucose experiments. 
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Successful and related results of the following analyses reveal the in vitro model’s ability to mimic 
the structure and placental transfer of glucose in an in vivo human placenta. More importantly, the 
model’s ability to replicate glucose transfer rates provides evidence that the model is prepared for 




  The progress of the in vitro model for the replication of the physiology and glucose transfer 
across the in vivo placental barrier has played a significant part in the replication and comparison 
of medicated-drug reactions between the placenta-on-a-chip and in vivo human placenta. For 
example, the testing of glyburide across the placenta-on-a-chip proved to be successful in 
replicating the common occurring effects that the in vivo placenta release during glyburide intake. 
Glyburide is a common medication that is prescribed to pregnant women to combat and contain 
diabetes. However, the traceability of glyburide is nearly undetectable in the fetal circulation as 
reported by the success of the ex vivo clinical and perfusion models.[131, 135-136] 
Nonetheless, with the development of the placenta-on-a-chip, Blundell et al. have 
efficiently imitated the usual effects that the human placenta releases when glyburide is diffused 
across the placental barrier (Figure 2.8). The study began when Blundell et al. introduced glyburide 
into their placenta-on-a-chip. The continuous perfusion of BODIPY-conjugated glyburide diluted 
in serum-free DMEM/F-12K to a final concentration of 1×10−6 M was perfused through for the 
maternal channel, while the EGM-2 medium was injected into the fetal channel to examine 
glyburide transport. After a 30 min equilibrium phase, the outflow was collected from the fetal 
compartment in 30 min intervals and then analyzed with a microplate reader. Next, to validate the 
presence of breast cancer resistance proteins (BCRP), Ko143 (150×10−9 M in DMSO), an inhibitor 
of BCRP, was included in the drug-containing medium and perfused in the maternal channel.[131]  
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Figure 2.8. Glyburide and Heparin perfused across Blundell et al. placenta-on-a-chip: (a1,a2) Maternal and 
fetal glyburide concentrations are expressed between two studies, control perfusion and perfusion with 
Ko143. (b1,b2) Ko143 expressed in fetal channel shows minimal variation from the control group. (c) 
BCRP (red) is expressed in BeWo cells. (d) BeWo BCRP expression shown in cross-sectional view. Scale 
bars, 36 µm. Reproduced with permission from [131]. Copyright © 2018, John Wiley and Sons.   
After testing was completed, Blundell et al. began interpreting their data. Low 
concentrations were measured throughout the first 3 h due to the large absorptions from the PDMS 
slabs, and trophoblast cells. Unexpectedly the concentrations began to rise in the last 3 h of the 
experiment, resulting in glyburide rates of 5.6% which were relatively close to the ex vivo model’s 
glyburide rates from 0.62% to 3.9%. These sudden rises were most likely caused by BCRP-
medicated active transport of BODIPY-glyburide, in which the placental barrier was absorbing 
BODIPY-glyburide back into the maternal circulation. Nevertheless, the similar results between 
the in vitro and ex vivo model reveal that the simple in vitro chip’s design can duplicate the active 
drug transport of an in vivo human placenta, like the complicated and underdeveloped ex vivo 
model was able to accomplish.[131] Observations were also taken from the constant fetal 
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concentrations of glyburide. The fetal concentrations turned out to be lower than the maternal 
concentrations. In addition, microscopic imaging was carried out to determine why there was 
differences in the fetal and maternal concentrations. Based on microscopic imaging, observations 
conclude that BeWo cells were predominantly in control of glyburide transport. This observation 
indicates the fact that BeWo cells in the in vitro model were one of the most significant aspects 
towards the transporting of glyburide across the chip’s barrier, which happens in most cases in an 
in vivo placenta.[131] 
Blundell et al. microengineered placental barrier was also analyzed to determine the 
presence of BCRP, major efflux transporter in the placental tissue. The BCRP plays a critical role 
in preventing medicated-drugs from entering the fetal compartment of the placenta, making the 
presence of BCRP essential for the in vitro model to mimic the diffusion of drugs across the 
placental barrier completely. Based on fluorescent images, BCRP turned out to be distributed 
throughout the trophoblast channel of the in vitro model, which is parallel to the in vivo human 
placenta. Nevertheless, including Ko143 in the perfusion of BODIPY-conjugated glyburide 
reduced the transport function BCRP and prevented the BeWo cell from transferring glyburide 
back into the maternal channel. This discovery supports the presence of BeWo cells when 
glyburide is moved across the placental barrier, supporting the previous argument. Therefore, the 
placenta-on-a-chip’s progress, pertaining towards the model’s ability to reproduce the natural 
reactions that are released from an in vivo placenta when confronted with glyburide, reveals one 
of the chip’s highlighted accomplishments.[131]  
 
2.6.3. Heparin 
Not only was there success pertaining towards the replication of glyburide on the in vitro 
model, but the replication of the natural effects of heparin in the placenta-on-a-chip was carried 
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out successfully as well. Heparin is a commonly used medication to prevent vein thrombosis and 
arterial thromboembolism. Not to mention, heparin is a commonly used anticoagulant medication 
to assess the microengineered placental interface’s barrier integrity. Blundell et al. assessed 
heparin transport across the placental membrane and measured the intensity of fluorescence 
outflow from the microchambers of the placenta-on-a-chip. The analysis of heparin transport was 
also carried out in order to determine if the in vitro model can efficiently duplicate the maternal-
fetal interface and restrictive barrier of an in vivo placenta. Using heparin as a medicated drug 
subject additionally allowed researchers to verify that their in vitro model fully imitates the 
common reactions from an in vivo placenta in order to acknowledge the model is entirely 
practical.[131]  
At the beginning of the study, Blundell et al. diluted green fluorescent fluorescein-heparin 
conjugate to a concentration of 0.05 mg mL−1 in DMEM/F12K medium. Subsequently, the diluted 
fluorescein-heparin was injected into the maternal compartment of the placenta-on-a-chip. 
Following 5 h of perfusion, the outflow was then collected from both channels. The fluorescence 
levels were then quantified with a microplate reader. The following procedure was carried out for 
both the co-culture and bare membrane (acellular) conditions in the microchip. Briefly, the 
acellular system included a bare semipermeable membrane without the support of trophoblast and 
endothelial cells; however, the co-culture system was supported with BeWo cells and HPVECs, 
and consisted of lower fluorescence intensity.[131]  
 Results from the acellular devices indicated high fluorescence levels and a concentration 
of 11.3% of the maternal compartments’ initial absorption. High fluorescence levels and low 
concentrations prove that the acellular device efficiency replicated the natural reactions released 
from an in vivo placenta from heparin intake. The co-culture system resulted in a fluorescent final-
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fetal-concentration of 0.2% of the maternal concentration initial value. This lower concentration 
that of the acellular device can be explained by the presence of BeWo cells and HPVECs. 
Nonetheless, the 11.3% and 0.2% minuscule concentration percentages reveal that Blundell et al. 
placental barriers can effectively mimic the case that heparin reported to be not transported across 
the placenta barrier due to its larger molecular size. In this case, the placenta-on-a-chip can 
successfully replicate the natural occurring reactions from heparin intake, in which the in vivo 
placenta’s common response from heparin is to show aggressive rejective behavior. Testing 
heparin in the in vitro model provided support for the fact that the placenta-on-a-chip possesses 
the ability to test for medicated-drug intake reactions. More importantly, though, the study’s 
success establishes that the microchip’s similar fabrication processes with the glucose and 
glyburide studies prove that the placenta-on-a-chip is closing in on becoming the practical model 
for revolutionizing pharmaceutical drug testing.[131]    
 
2.6.4. Bacterial Infection   
Zhu et al. chose to model placental inflammatory responses to bacterial infections through 
their microfluidic device (Figure 2.9). Through the establishment of the microfluidic device, they 
were able to construct a placenta-on-a-chip that enabled them to analyze tissue and cellular 
responses from bacterial infections. Bacterial infections are a common cause of placental 
inflammation that can cause damage to fetal organs and transplacental infection in the growing 
fetus. In return, these damages can cause inflammatory response syndrome, sepsis and other 
underlying diseases within the human placenta. In these cases, these responses can lead to short-
term and long-term limitations during fetal development stages. Therefore, scientists need to be 
incorporating bacteria into the placenta-on-a-chip if they want to account for these limitations  and 
fully replicate the physiology of the human placenta in vitro.[129] Bacterial transformation and 
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infection within Zhu et al. chip began with the cultivation of gram-negative Escherichia coli (E. 
coli) labeled with a green fluorescence protein (GFP) from LB broth. Escherichia coli is a 
dominant bacterium found within the intestines of humans and other animals, which happens to be 
harmful in most cases. Cultivation took place for 12 h at 370C and 5% CO2. Subsequently, the E. 
coli were resuspended in DMEM/F-12K medium and immunized with trophoblast medium in the 
upper microchannel of the microfluidic device. After 6 h of immunization, the cells were prepared 
for biological analysis.[129]  
Figure 2.9. Bacterial infections were introduced into Zhu et al. placenta-on-a-chip. (a1,a2) Maternal 
macrophages behavior in the maternal-fetal interface during bacterial infection (GFP expressing bacteria). 
(b1,b2) Images depict proliferated GFP-expressing bacteria in the microchip. (c1-c6) Fluorescence 
microscopy shows the behavior of BeWo and THP-1 cells in E. coli (d) Inflammatory genes in BeWo cells 
were stimulated with E. coli and were represented by a RT-PCR quantitative analysis. Scale bars, 100 µm. 
Reproduced with permission from [129]. Copyright © 2018, American Chemical Society. 
Results and data from biological investigation concluded that the immunization with the 
E. coli and trophoblast cells resulted in high amounts of inflammatory cytokines, which includes 
Interleukin-1α (IL-1α), IL-1β, and IL-8. In other words, there were increased levels of 
inflammatory from the immune responses (IL-1α), cell proliferation (IL-1β), and the host defense 
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mechanisms (IL-8). These increased levels of inflammatory responses resulted in a significant 
amount of death in the trophoblast and endothelial cells. The conclusion from these results reveals 
that the placenta-on-a-chip was able to mimic the inflammatory reactions on an in vivo placenta 
when confronted with E. coli, based on the similarly increased levels of inflammatory responses. 
Nevertheless, conclusions from Zhu et al. study also indicated that the BeWo cells activated the 
circulating macrophages when inflammatory began to develop along the maternal side of the chip. 
These activation interactions are common in an in vivo human placenta, since the macrophages 
responsibilities include the protection of the maternal and fetal organs from bacterial inflammatory 
infections. Thus, these results show the placenta-on-a-chip’s capabilities to replicate the bacterial 
interactions and behaviors between the macrophages and trophoblast and BeWo cells in vitro.[129] 
 
2.6.5. Nanoparticles 
The placenta-on-a-chip has been applied for, fluid analysis, medicated-drug testing, 
physiological examinations; however, Yin et al. used their in vitro model for nanoparticle (NP) 
analysis (Figure 2.10). The study included a common NP (TiO2-NPs) that are environmentally 
exposed to the majority of pregnant women. Unfortunately, studies lack on this subject of research, 
so the adverse effects NPs on the placental barrier are lesser known. However, through the 
fabrication of Yin et al. placenta-on-a-chip, they were able to extrapolate data to explore the effects 
TiO2-NPs imposed on their micro-engineered placenta while bringing awareness to this 
overlooked NP.[132] 
 Yin et al. began this experiment by exposing their fabricated placenta-on-a-chip with NPs. 
The process began by injecting DMEM/F12-K medium with TiO2-NPs at a concentration of 50 or 
200 μg mL−1 into the maternal channel at a rate of 20 μL h−1 for 24 h. Next, monocyte adhesion  
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Figure 2.10. Nanoparticle exposure across placenta-on-a-chip: (a1-a3) Schematic shows TiO2-NPs being 
perfused in the maternal channel and transferring into the matrix in the middle channel after 24 h. (b1-b3) 
ROS levels were analyzed in the BeWo cells with NPs exposure. Scale bars, 50 µm. (c1,c2) The diagram 
represents perfused differentiated THP-1 cells in the maternal channel. (d1-d3) After NPs exposure, the 
trophoblast cells were analyzed for THP-1 adhesion. Scale bars, 100 µm. Reproduced with permission from 
[132]. Copyright © 2019, Elsevier. 
analysis was performed. This included differentiating monocyte THP-1 cells into macrophages, 
and then perfusing them into the channels at a flow rate of 40 μL h−1 for 30 min. The channels 
were then washed with PBS 3 times before imaging was taken place. Once imaging was acquired 
from a confocal microscopy, Yin et al. began ROS detection in their cells. The inspection was 
conducted using a ROS Assay kit.[132] 
The findings Yin et al. gathered begins with their ROS fluorescence image discoveries. The 
production of ROS, a natural occurring metabolism by-product in trophoblast, was used to study 
when detecting for NPs exposure. On the maternal side of the chip, when lower NPs concentrations 
were introduced, ROS generation was almost nondetectable. Once levels were increased, ROS 
generation activated substantially, which is observable based on the decrease of cells. Additionally, 
once the NPs transferred across into the fetal channel of the microchip, endothelial cells began to 
die off. These increased distributions were in theory, enhanced by the close-fitting cellular 
junctions within the placental barrier. Therefore, tight junctions are possibly more sensitive to 
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environmental stress, NPs. Nevertheless, since the placental barrier includes more than just 
endothelial and trophoblast cells, Yin et al. decided to analyze the effects the NPs had on 
macrophages.[132]  
During the procedural examinations, monocyte adhesion was included. Based on the 
discussion of Zhu et al. study on bacterial infections, monocytes are prominent for cellular and 
tissue defense from outside pathogens.[132] Once data was collected from the NPs channel 
exposure, macrophages were introduced into the maternal side of the chip. Observations 
discovered that the macrophages adhered to the trophoblastic cell layer. This behavioral reaction 
revealed the significant immune system changes towards NPs. In other words, macrophages were 
able to detect the NPs and determine the harmfulness of their nature. Moreover, the results of the 
study concluded the destructive nature of NPs, and the damaging effects they impose on the 
placental barrier. In this case, these destructive behaviors can have a long-term impact on the 
placenta, and even worse, the fetus.[132] 
Therefore, in conclusion of the study, there are two take ways. One, the fabrication of the 
placenta-on-a-chip was carried out similarly with the previous elaborated studies, providing 
consistency between analyses. More importantly, though, the placenta-on-a-chip was used to study 
an overlooked pathogen- a pathogen that scientist have not been paying close attention to when 
searching for mutational defects in the fetus and placental barrier. So, in this case, the study 
provides one of the first documentation on the effects NPs imposes on the placental barrier, based 
on their placenta-on-a-chip. In this case, this study will improve placenta-on-a-chips progress for 
testing medicated-drug testing, considering nanoparticles play a factor in placental mutations and 
fetal birth defects.[132] 
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2.6.6. Caffeine  
While placenta-on-a-chip has undergone fluid flow, medicated-drug, bacterial infection, 
and nanoparticle testing, Pemathilaka et al.[133] provides one of the first studies of caffeine 
transport across the placenta using a placenta-on-a-chip model. Caffeine happens to be one of the 
most widely consumed stimulants in the world and consisting as a main ingredient in coffee, tea, 
chocolate, soda, etc. In this case, the over-consumption of caffeine can have damaging effects on 
the fetus. So, in this study, Pemathilaka et al. fabricated a placenta-on-a-chip to assess the 
overlooked behaviors the xenobiotic compound is imposing on their chip. This study is further 
discussed in Chapter 2. 
 While the placenta-on-a-chip is one of the most recently developed approaches toward 
medical drug treatment, the model has acquired a significant amount of progress regarding fluid, 
medicated-drug, bacterial infection, nanoparticle, and xenobiotic testing. With limited testing and 
analysis, the success to fail ratio for the placenta-on-a-chip is substantially high, considering that 
the model was developed relatively recently. A substantial amount of progress has been gained 
from the broad spectrum of testing in the in vitro model’s placental barrier: mimicking glucose 
transfer, glyburide and heparin drug reactions, bacterial infections, and nanoparticle and caffeine 
expose responses. The variety of studies, especially the testing of fluid transporters and bacteria 
and xenobiotic compounds, improves the overall functionality of the in vitro approach, 
reproducing the physiological characteristics and common reactions that an in vivo placenta 
releases when confronted with medicated-drugs. Most importantly, the consistency between the 
experiments and their fabrication processes for their microengineered in vitro models has played 
a vital role towards the chip’s practicality, when comparing data between different fluid, 
pharmaceutical, bacterial, and xenobiotic intake tests. Therefore, the testing of glucose, glyburide, 
heparin, bacterial infections, nanoparticles and caffeine have proven to be significant for the better 
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understanding of their interactions with the human placental barrier. As researchers continue 
improving the fabrication process, and conducting successful medical treatment tests on the in 
vitro chip, the placenta-on-a-chip could potentially become one of the most demanded products in 
the pharmaceutical and medical industry. 
  
2.7. Challenges of Placenta-on-a-Chip  
 
Figure 2.11. Pregnant mother surrounded by recently developed placenta-on-a-chips. (a) Miura et al. used 
their placenta-on-a-chip to determine whether fluid shear activates microvilli formation and TRPV6. [105] 
Scale bar, 1 cm. Reproduced with permission from Miura et al. [105]/CC BY. (b) Blundell et al. microchip 
was analyzed for glucose transport studies. Reproduced with permission from [5]. Copyright © 2016, RSC. 
(c) Blundell et al. microchip was used for heparin and glyburide transport studies. Reproduced with 
permission from [131]. Copyright © 2018, John Wiley and Sons. (d) Zhu et al. studied bacterial infections 
within their microfluidic device. Reproduced with permission from [129]. Copyright © 2018, American 
Chemical Society. (e) Yin et al. analyzed nanoparticle exposure into their placenta-on-a-chip. Reproduced 
with permission from [132]. Copyright © 2019, Elsevier. (f) Pemathilaka et al. perfused caffeine across their 
microengineered barrier, and examined the channels respective concentrations.[133] Reproduced with 
permission from Pemathilaka et al.[133]/CC BY 
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Although the placenta-on-a-chip (Figure 2.11) has made a substantial amount of progress 
towards the testing of medicated-drugs across the microengineered placental barrier, the model 
was developed fairly recently compared to the in vivo and ex vivo models. One of the most 
significant problems when defending the placenta-on-a-chip’s accomplishments is the fact that the 
model has only had a few efficient pharmaceutical intake tests performed on the chip’s 
microengineered placental barrier. This is largely because scientists have been devoting the 
majority of their time in the past few years modifying the fabrication process for the placenta-on-
a-chip. Ironically, though, while scientists have been investing a considerable amount of time 
improving the chip’s structural and functional components, researchers lack the replication of 
prominent physiological characteristics of the placental barrier. For example, the placenta-on-a-
chip lacks the testing of fatty and amino acids, which are essential characteristics when predicting 
the capability and reactiveness of the chip, and mimicking the physiology of the human placenta.[5] 
However, unlike the in vivo and ex vivo model, the in vitro approach has seen a significant amount 
of testing in the model’s early development stages compared to the previous models.  
Not only are there issues pertaining the model’s experience with pharmaceutical testing, 
but also faces challenges towards the chip’s aptitude to perform complicated tests, and control and 
distribute PDMS. For example, when the functionality and complexity of the 3D co-cultured model 
of the cell increases, analysis of the chip becomes more difficult to perform high-resolution 
screening of the tissue and to visually locate the tissue.[137] In addition, when analyzing for 
biological responses the chip’s small cell volumes, when compared to an in vivo placenta, give rise 
towards detection sensitivity issues for drug absorption and cellular interactions. Therefore, the 
mapping and interpretation of the chip’s clinical endpoints make the data difficult for pharmacists 
and scientists to translate to patients and themselves.[72] There are also limitations dealing with 
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PDMS. PDMS has shown to reduce the pharmacological and drug absorption reactions, because 
of the PDMS consuming hydrophobic molecules. PDMS also lacks the ability for vast-scale 
manufacturing, because the PDMS fabrication process is intended for laboratory prototype only. 
In this situation, the adoption of this technology into the pharmaceutical and medical industry will 
make the process difficult for large-scale industries to obtain PDMS.[72, 131, 138-140] Furthermore, the 
complexity and limitations with the placenta-on-a-chip and PDMS are both major disadvantages 
when considering the operation and control of the chip’s abilities and performance.  
More challenging, though, the placenta-on-a-chip lacks the maintenance for human cells 
and accountability of placental alterations during pregnancy. Scientists can agree that the 
maintenance of confluent trophoblast cells is challenging. In order to maintain and control 
confluent trophoblast cells, patience and precise cellular cultivation are needed for the operation 
and control of the model to function properly. Maintaining and preventing cellular contamination 
is also difficult when considering that the contamination of the cells will lead towards false results 
and insignificant data. Additionally, there needs to be new developments within the chip in order 
to account for alterations in an in vivo placental barrier throughout pregnancy. The human placental 
barrier goes through many alterations in the course of pregnancy. Thus, the model must account 
for these alterations in order for the chip to entirely mimic pharmaceutical intake of an in vivo 
placenta during the course of an entire pregnancy.[131] In this case, if the model is unable to account 
for placental developments during pregnancy, the chip will oppose the model’s own goal of being 
fully practical. Nonetheless, if scientists continue improving upon the chip’s performance and 
sustainability of more challenging analysis, then the model’s advantages will overshadow the 
placenta-on-a-chip’s low track record of tests, complexity of transability and evaluation, 
maintenance of PDMS and cells, and other disadvantages.    
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The continuation of support and funding for the placenta-on-a-chip will assist scientists to 
progress improvements and developments on the chip’s overall functionality. As researchers 
continue innovating upon the in vitro approach, scientists will be able to conduct an array of tests 
across the microengineered barrier, other than pharmaceutical testing. For example, the 
experimentation and analysis of diseases and bacteria could be tested more frequently when the 
model reaches a sturdier compatible barrier. Scientists will also be competent to possibly use the 
in vitro model to gain new knowledge on the development stage of the fetus. For instance, there 
will be gains in the understandings on how slower or faster, or altered or damaged developments 
in the placenta impact the fetus’s growth. Nevertheless, the practicality of a universal model was 
discussed in detail, which dealt with the fact that the model must have a concrete procedure and 
method that can fully imitate the physiological characteristics of an in vivo human placenta, and 
be carried out in the same manner for all medical related testing in order for the comparison of 
data to take place. The development of a practical model that can run medicated intake tests is 
important towards the better understanding of the effects that pharmaceuticals impose on the fetus 
and placental barrier. In this case, the placenta-on-a-chip as explained throughout most of the 
paper, was discussed in detail on how this practical model will revolutionize pharmaceutical 
testing for a better understanding on how these medicated-drugs affect the human placenta when 
compared to the in vivo and ex vivo approaches. In conclusion, the application and progression of 
the placenta-on-a-chip’s testing of medicated-drugs and improved understanding of the human 
placenta will help scientists decrease birth defects from medicated-drugs, and develop a better 
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Abstract  
Due to the particular structure and functionality of the placenta, most current human 
placenta drug testing methods are limited to animal models, conventional cell testing, and 
cohort/controlled testing. Previous studies have produced inconsistent results due to physiological 
differences between humans and animals and limited availability of human and/or animal models 
for controlled testing. To overcome these challenges, a placenta‐on‐a‐chip system is developed for 
studying the exchange of substances to and from the placenta. Caffeine transport across the 
placental barrier is studied because caffeine is a xenobiotic widely consumed on a daily basis. 
Since a fetus does not carry the enzymes that inactivate caffeine, when it crosses a placental barrier, 
high caffeine intake may harm the fetus, so it is important to quantify the rate of caffeine transport 
across the placenta. In this study, a caffeine concentration of 0.25 mg mL−1 is introduced into the 
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maternal channel, and the resulting changes are observed over a span of 7.5 h. A steady caffeine 
concentration of 0.1513 mg mL−1 is reached on the maternal side after 6.5 h, and a 0.0033 mg 
mL−1 concentration on the fetal side is achieved after 5 h. 
 
3.1. Introduction 
Caffeine is one of the most popular and widely consumed stimulants across the globe.[1] 
Coffee, tea, and cocoa are the primary natural sources of caffeine. Both health authorities and 
regulatory bodies have raised concerns about consumption of caffeine‐enhanced food and 
beverages because of the increased availability of caffeine‐enhanced food products containing 
synthetic caffeine.[2] Because caffeine is found not only in food and beverages, but also in 
prescription and over‐the‐counter medications, many pregnant women are very likely to consume 
caffeine in some form, so they may risk exposing underdeveloped fetuses to this behaviorally 
active substance. There are concerns that overly heavy caffeine consumption may harm the fetus, 
since pregnant women require a half‐life 1.5 to 3.5 times greater to metabolize caffeine than non‐
pregnant women, possibly causing caffeine to remain in body tissues for longer periods of time. 
Caffeine has been found on locations within the fetal compartment, suggesting caffeine transport 
across the placental barrier, and since a fetus would have difficulty in metabolizing caffeine due 
to lower levels of enzyme production in its developing liver, there is a real possibility that caffeine 
exposure could damage the fetus.[1, 3] Because of undetermined effects from maternal caffeine 
intake on the fetus and the increased number of caffeine products available for prenatal 
consumption, health authorities such as the World Health Organization (WHO) and the Food and 
Drug Administration (FDA) have developed recommendations restricting caffeine intake during 
pregnancy and declaring caffeine consumption during pregnancy a global healthcare problem.[3-5] 
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Over the last decade, organ‐on‐a‐chip technology has grown to become one of the most 
popular alternatives for drug testing and toxicology in vitro. Its aim is to create a 3D 
microenvironment reminiscent of specific human organs as a means for replicating their 
functionality.[6] The placenta has been one of the most difficult organs to replicate using organ‐on‐
a‐chip because it is a temporary organ that develops only during pregnancy and changes its 
structure and functionality over the course of the gestational period. To study this vital organ, in 
vivo, ex vivo, and in vitro tests have been conducted. In vivo studies conducted on rats and baboons 
have yielded inconsistent results.[7-9] It is difficult to transfer the results from an animal testing 
model to a human model because placenta development is different in different mammals.[10-13] For 
example, in humans, glucose transport through the placental barrier is mediated by GLUT1 glucose 
transporters, while in mice it is mediated by GLUT3 transporters.[14] This difference shows why 
experiments using mice can yield lower glucose transfer rates than those found in similar 
experiments using human placentas. Previous studies have reported that in vitro 
microphysiological placenta systems are capable of exhibiting similar levels of glucose transport 
as those of actual placenta.[14-15] Moreover, in another study, the transport of two xenobiotic 
substances, heparin and glyburide, was studied using a bioengineered placental model, 
demonstrating the capability of a placenta‐on‐a‐chip model to successfully mimic at least some of 
the physiological functions of the human placenta.[16] It has also been shown that these in vitro 
models are capable of mimicking placental inflammatory behavior from a placenta attacked with 
a bacterial infection.[17]  
Even though humans are closely related to many other mammals, there is no yolk sac 
placentation in humans, and an allantoic stalk rather than an allantoic sac is present in a human 
placenta.[18] This makes it challenging to compare the results of experiments conducted on 
66 
placentas of other mammals to results of studies conducted on human placentas. Ex vivo studies 
in humans have also been conducted by obtaining placentas immediately after childbirth or 
cesarean sections.[19] These human studies only provide opportunities to study placentas and gain 
insight from women in their final term of pregnancy. Difficulty in obtaining consent from women 
for such participation in such studies and gaining access to placentas before they become no longer 
viable makes these studies difficult to conduct. Moreover, ethical issues may limit experimental 
research of this type, and observational studies may be difficult to perform because the women 
could be from a group self‐selected for testing a particular drug.[20]  
During pregnancy, both endogenous substances and xenobiotic substances consumed by a 
pregnant woman can pass through the placental barrier, possibly causing severe damage to a fetus 
either before or after birth. For example, an exogenous compound with the chemical nomenclature 
1,3,7‐Trimethylpurine‐2,6‐dione, commonly known as caffeine, is quite often consumed 
worldwide by pregnant women on a daily basis by way of ingesting coffee, tea, energy drinks, 
chocolate, etc., because it acts as a stimulant for the central nervous system 
(CNS).[20] Unfortunately, it has been found that such increased intake of caffeine by pregnant 
women can result in birth weight (BW) reduction in newborn children, or in reduced neonate size 
for its gestational age (SGA).[20-22] A meta‐analysis of 32 studies suggests that caffeine intake is 
associated with an increased risk for reduction in BW, and another meta‐analysis of 26 studies 
appeared to show a 43 g weight reduction in newborn children whose mothers appeared to be 
heavy caffeine consumers.[21-22] Despite these findings, it has never been recorded that caffeine 
directly causes BW reduction, also known as intrauterine growth retardation (IUGR).[23-29] While 
both meta‐analyses exhibited some correlation with caffeine intake and BW, inconsistencies found 
in these studies suggest that there remains a need to identify a proper method for measuring exact 
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caffeine levels crossing the placental barrier when a prospective mother consumes a certain amount 
of caffeine. Note that the effects on a fetus due to excessive intake of caffeine by pregnant women 
are beyond the scope of this study because it primarily focuses on the amount of caffeine 
infiltrating a placental barrier. 
Caffeine is easily absorbed by the placental barrier and crosses the barrier freely.[23] Since 
the primary enzyme responsible for caffeine metabolization, cytochrome P450 1A2, is absent both 
from the placenta and the fetus, the rate of metabolism of caffeine depends totally on the 
metabolization capacity of pregnant women.[24] One study states that the half‐life of caffeine has a 
range of 6–16 h in pregnant women compared to that for non‐pregnant women, i.e., 2–8 h.[25-
26] According to guidelines provided by the WHO and FDA, the intake of caffeine during 
pregnancy should not exceed 300 mg per day, making it necessary to measure a pregnant woman's 
concentration of caffeine perfused into the fetus in relation to her total caffeine intake.[4, 29]  
Our placenta‐on‐a‐chip device is designed to represent the trophoblastic epithelium and 
endothelium of the maternal interface and the fetal interface in a human placenta, respectively. 
The chip was designed to carry two cell lines to represent both the maternal and the fetal sides. A 
porous membrane was placed between the two channels to serve as a barrier between the two 
bloodstreams. This membrane acts as an extracellular matrix (ECM) to provide support for 
surrounding cells used in our design. Human umbilical vein endothelial cells (HUVECs) and 
trophoblasts cells (BeWo) were respectively chosen to represent the endothelium in the fetal 
interface and the epithelium in the maternal interface. This work will enable us to establish a 
platform for studying the pharmacokinetics of different xenobiotic drugs across the placental 
barrier, and also enable us to examine the safety of drugs administered to pregnant women. 
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3.2. Results and Discussion  
3.2.1. Cell Growth and Characterization on Membrane 
The HUVECs and BeWo cocultured microfluidic device provided a relevant environment 
for representing the propagation of a human placenta. The human placenta in vivo consists of three 
main parts: the epithelium, the endothelium, and the placental barrier. As intended, we were able 
to replicate an in vivo–like microsystem with HUVECs representing the endothelium, BeWo cells 
representing the epithelium, and a semipermeable membrane representing the placental barrier. 
CellTracker results (Figure 3.1a–d) showed a proliferation of cells over time and cell 
characterization was used to further study the formation of a placental barrier–like interface used 
to replicate and mimic placenta‐related physiology. During medium perfusion, cells were able to 
cover the entire area of both sides of the membrane within 24–30 h from the cell seeding. Cell 
adhesion on the porous membrane is an important step in properly representing each cell line, and 
ECM macromolecules play an important role in proper growth and normal function of primary 
cells.[30] The most important cell‐adhesion control variable was the cell adhesion time. Various 
time periods were tested to identify the optimal time for cells to reach solid attachment. Another 
important parameter affecting cell viability on the channel was the flow rate. Since high flow rates 
produce high levels of shear stress on the channel walls, and can thereby force attached cells to 
detach from the membrane and flush out of the device, we tested different flow rates to seek the 
best results while also satisfying the previously discussed conditions. In the upper channel where 
BeWo cells were introduced, cells began forming a 3D structure and thereby affected long‐term 
cell growth in the upper channel. As cell coverage increased, the space remaining for the medium 
to cross the channel had decreased, causing medium flow to exert pressure on the cells. 
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Figure 3.1. Cells in channels after 48 h of media perfusion. (a) BeWo cells with RFP grayscale imaging, 
(b) BeWo cells with RFP color imaging, (c) HUVECs with GFP grayscale imaging, (d) HUVECs with GFP 
color imaging, (e) BeWo cells showing epithelial adherence junctions with E‐Cadherin and Nuclei labeled 
with DAPI staining, (f) HUVECs showing endothelial adherence junctions with VE‐Cadherin and Nuclei 
labeled with DAPI staining, scale 50 microns and g) fluorescence intensity measured using dextran for 4 h, 
data represented as a fraction of maternal intensity/fetal intensity. n = 3 independent experiments. Data are 
presented as mean (±SD). 
When fabricating a placental‐barrier‐like semipermeable membrane, it is important to 
verify the formation of tight cell–cell junctions. E‐cadherin is considered to be an important 
molecule when seeking to maintain cell–cell adhesion in the epithelial cell layer because it is 
restricted to regions of adherence junctions.[31] We used E‐cadherin present on trophoblast cells to 









days, BeWo cells were stained with anti‐E‐cadherin and scrutinized for red fluorescent protein 
(RFP). As shown in Figure 3.1e, BeWo cell–cell boundaries tested positive when stained for E‐
cadherin, verifying existence of tight junctions across the epithelial cell layer. Tight junctions in 
the endothelial cell layer ensure tissue integrity and play a vital role in maintenance and control of 
endothelial cell contacts.[32] VE‐cadherin was used to investigate cell–cell interactions and the 
formation of tight junctions on HUVECs that represent the endothelium. Similarly, after 3 days of 
medium perfusion, HUVECs were marked with anti‐VE‐cadherin and analyzed for green 
fluorescent protein (GFP). As shown in Figure 3.1f, VE‐cadherin was detected on cell–cell 
partitions, verifying the occurrence of tight junctions in the endothelial cell layer. The E‐cadherin 
and VE‐cadherin‐labeled cell–cell boundaries implied the formation of tight junctions and verified 
that both the epithelial and endothelial cell layers consisted of a confluent monolayer of cells on 
the membrane. 
Placental barrier permeability was evaluated using 3000 MW fluorescein–dextran anionic 
probes. When dextran was introduced to the maternal side, fluorescence intensities on both the 
maternal side and the fetal side were recorded, and the data represented as a fraction, with maternal 
intensity the numerator and fetal intensity the denominator, as shown in Figure 3.1g. We observed 
that, while maternal fluorescence increased over time due to the dilution of the dextran‐mixed 
medium by the remaining medium in the channels and by the tubing, fetal fluorescence intensity 
remained at a lower level. Even though a few molecules were diffused from the maternal side to 
the fetal side across the membrane, overall fetal intensity remained insignificant over time, 
verifying the integrity of the placental‐barrier‐like semipermeable membrane. 
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3.2.2. Quantitative Analysis of Caffeine Transport 
3.2.2.1. Concentration of Caffeine Transported through Placental Barrier 
Before calculating caffeine concentrations, we plotted the data obtained from the area 
under the curve for each chromatogram with respect to time, as shown in Figure 3.2, and the fetal 
side (Figure 3.2a) of the control (samples collected from a chip consisting of a bare membrane 
with perfusing EGM and F‐12K) showed more fluctuation in terms of the number of counts 
(representing the area) with a positive gradient with respect to time up to t = 6.5 h. Between t = 
6.5 h and t = 7.5 h, concentrations (represented by the number of counts) sought to reach a steady‐
state while achieving a peak‐level of caffeine diffusion through the placental barrier. Conversely, 
the actual data (from chips with cells and medium) show less data variability, with a positive 
gradient, but data remained in a lower range than in the controlled tests. The actual data also 
exhibited reaching a peak diffusion between t = 5 h and t = 7.5 h. On the maternal side 
(Figure 3.2b), control data always remained lower than actual data, but it exhibited greater 
fluctuation than the actual data while the system was moving toward its optimum diffusion stage, 
and this trend was also observed on the fetal side. The data show attainment of steady‐state 
between 6 and 7.5 h for actual data. 
Using data obtained from both the maternal and fetal calibration curves, individual 
quadratic curves were fitted and equations with a 95% confidence level found for them. 
Equations 3.1 and 3.2 represent curves fitted for EGM (fetal) and F‐12K (maternal), respectively. 
Af = −8.06e
8Cf
2 + 5.80e8Cf + 3.46e
5   (3.1) 
Am = −2.04e
8Cm
2 + 3.97e8Cm + 4.64e
6              (3.2) 
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Where A and C represent the area under the curve from the liquid chromatography mass 
spectrometry (LCMS) method and the calculated caffeine concentration, respectively. Roots were 
obtained from each equation for both maternal and fetal caffeine transport. We neglected one root 
under the condition: C ≤ 0.25 mg mL−1 because the highest caffeine concentration introduced was 
0.25 mg mL−1 on the maternal side.  
 
Figure 3.2. Area under the curve for each chromatogram from LCMS, which were generated for each 
sample collected from both the maternal and fetal outlet after every 30 min. (a) Chromatogram area output 
for EGM (fetal side). (b) Chromatogram area output for F‐12K (maternal side). Actual tests have both cells 
in the chip and the control has just the bare membrane with media perfusing through the channels. n = 3 
independent experiments. Data are presented as mean (±SD). 
Figure 3.3 a,b shows calculated concentrations with respect to time that followed the same 
trend as in Figure 3.2. Examination of caffeine concentrations for actual tests on the fetal side 
(Figure 3.3a) reveals a more conclusive result than that for concentrations represented by areas 
under the curve (Figure 3.2a). In this study, we investigated both the steady‐state concentration 
and with the amount of time required to reach this condition. Knowing steady‐state concentrations 
on the maternal and fetal sides will assist in verifying the safest dose of caffeine to be taken by a 
mother when a certain concentration is described in terms of the safe concentration level in the 
(a) (b) 
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fetus. Since this system was used only as a proof‐of‐concept to verify the caffeine transport across 
the placenta in vitro, only one caffeine concentration (0.25 mg mL−1) within the safe amount of 
caffeine according to FDA was tested. After 5 h, the caffeine concentration began to reach a steady‐
state of 0.0032 mg mL−1, and between 5 and 7.5 h, it maintained an average of 0.0033 mg mL−1 in 
steady‐state. Fetal caffeine concentration in controlled tests reached its peak at t = 6.5 h, and 
between 6.5 and 7.5 h it achieved its steady‐state at an average of 0.0179 mg mL−1. Similarly, 
analyzing the caffeine on the maternal side (Figure 3.3b) shows that steady‐state for the actual tests 
was achieved between 6 and 7.5 h at a value of 0.1513 mg mL−1 (average). During the controlled 
experiment, it was noted that steady‐state was achieved after 7 h at a caffeine concentration of 
0.1307 mg mL−1. After 7.5 h, we observed cells detaching from the membrane. At this point, we 
concluded that the system could no longer provide a confluent layer of cells and would therefore 
not adequately represent a system to be used for actual experiments. Such failure could be 
attributed either to effects of caffeine on the cells or flow phenomenon inside the channels. Further 
studies are required to identify or confirm reasons for underlying cell detachment. Steady‐state 
was defined at the point in time or time range where caffeine concentrations seemed to maintain a 
steady value with respect to time while caffeine continued to be introduced into the maternal side 
at a constant flow rate. 
A study on a physiologically based human model of a pregnant woman concluded that, 
after introducing caffeine, the concentration increased until it reached a steady‐state value.[33] In 
that study, multiple doses were introduced, and each time the peak concentration was increased 
until it reached a steady‐state condition. We introduced about 0.0938 mg of caffeine to the maternal 
side within 7.5 h through medium perfusion, and while we can relate our tests to a similar study 
using multiple doses over time, the doses were continuously given, possibly explaining why  
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Figure 3.3. Caffeine concentrations calculated for both the maternal and fetal sides. (a) EGM (fetal side). 
(b) F‐12K (maternal side). Actual tests have both HUVECs and BeWo cells on the chip and the control has 
solely the bare membrane with media perfusing through the channels. (c) Calibration curve for caffeine 
concentrations in EGM (concentrations ranging from 0.00001 to 0.25 mg mL−1). (d) Calibration curve for 
caffeine concentrations in F‐12K (concentrations ranging from 0.05 to 0.3 mg mL−1). n = 3 independent 
experiments. Data were presented as mean (±SD). 
Figure 3.2 a,b has multiple peaks but only reached a single steady‐state condition. Since we 
continuously perfused caffeine diluted medium for 7.5 h, continuous perfusion resulted in multiple 
peaks with only a single steady‐state region. In addition, concentrations reported in controlled 
experiments were significant in the absence of caffeine on either the maternal side or the fetal side 
because caffeine that perfused to the maternal side should come from either the maternal side or 




(PDMS) side walls in the maternal channel. This was not significantly observed in actual 
experiments due to the cell coverage in channels. 
While the collected volume might have only a minimal error, even this small error could 
affect the final calculated value. For example, while the expected volume within a 30 min perfusion 
period is 25 µL (with a flow rate of 50 µL h−1), only a small error in volume could dilute the 
medium with an incorrect volume of methanol. This error was minimized by measuring the volume 
of the sample collected during each 30 min period diluted with the correct amount of methanol. In 
Figure 3.2a, the number of counts measured at later time points (i.e., t = 6 h) at the fetal side 
showed the same standard deviation order value as the average. This was observed at early time 
points (i.e., t = 2 h) on the maternal side, as shown in Figure 3.2 b. Fluctuations of caffeine 
concentrations on the both maternal and fetal sides at later time points could be attributed to cell 
detachment, but earlier fluctuation of the maternal concentration could be a result of different 
medium dilutions with methanol, as mentioned earlier. Further studies are needed to find specific 
reasons for these errors. In Figure 3.3b, it was noted that the highest calculated caffeine 
concentration (0.2591 mg mL−1) was detected at t = 1.5 h. While this value is greater than the 
caffeine concentration introduced to the maternal side (0.25 mg mL−1), during the calculation 
process the fitted curves (in Figure 3.3 c,d) were made with a 95% confidence level and that error 
could affect the caffeine concentrations calculated on both maternal and fetal sides. 
 
3.2.2.2. Rate Transfer of Caffeine 
The rate of caffeine transfer was calculated for both maternal and fetal sides using the 





× 100      (3.3) 
Where ΔCf and ΔCm represent the change in caffeine concentrations in the fetal and 
maternal channels, respectively, during perfusion. Initial and final caffeine concentrations from 
both the maternal and fetal sides were used when calculating the values for ΔCf and ΔCm. To 
calculate the initial maternal and fetal caffeine concentrations, the values at a previous time point 
were used for both the actual and controlled experiments (Figure 3.4). Calculated rates were used 
to measure the change in rate of caffeine transfer with respect to the rate of caffeine transfer 
calculated at the previous time point (i.e., if the rate of caffeine transfer was calculated at t = 5 h, 
the values at t = 4.5 h were used as the initial concentrations). 
As shown in Figure 3.4, the transfer rates for actual tests (with cells) reflected less 
fluctuation when compared to the rate calculated for controlled tests (without cells), when more 
caffeine was introduced into the system. In actual experiments, the transfer rates calculated 
from t = 1 h to t = 3 h show a gradual decrease, followed by a sudden increase and another gradual 
decrease in caffeine transfer rate observed between t = 3 h and t = 5 h. Similar patterns were seen 
in transfer rates for the controlled tests from t = 1.5 h to t = 4 h. The frequent fluctuations were 
attributed to the constant perfusion of caffeine at 50 µL h−1 to the maternal side, although further 
investigation is needed to find the exact reasons for such fluctuations. It has been previously 
reported that the transfer rate of caffeine across a placental barrier depends also on its 
physiochemical properties such as its size (molecular weight), ionization yield, lipophilicity (Log 
P), and protein binding.[34] High‐permeability coefficients are observed for small polar molecules 
because such compounds pass readily through lipid membranes.[35]  
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Figure 3.4. The rate of caffeine transfer calculated at every 30 min for both the actual (with cells) and 
control (without cells) tests. The rates were calculated cumulatively using the values at previous time point 
as the initial‐maternal and initial‐fetal concentrations (i.e., if the rate of transfer is calculated at t = 6 h, 
values at t = 5.5 h were used as the initial‐maternal and initial‐fetal concentrations). n = 3 independent 
experiments. Data were presented as mean (±SD). 
Assertions about the amount of caffeine safe for consumption during pregnancy vary 
depending on the study referenced, and the FDA, taking into account for all the variations for this 
value has stated that any amount less than 300 mg per day is safe for pregnant women.[29] In our 
study, we used a concentration of 0.25 mg mL−1 of caffeine, less than the FDA‐specified amount 
(300 mg per day = 0.67 mg mL−1), for perfusion analysis. 
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3.3 Conclusions 
In this study, we successfully fabricated a placenta‐on‐a‐chip device using PDMS soft 
lithography techniques. After confirming that we had a confluent layer of cells, we used it to 
conduct caffeine transport analysis. A caffeine calibration curve was initially established to 
quantify the caffeine in collected media from both maternal and fetal channels. Using an integrated 
equation, caffeine concentrations in each media were calculated for each sample over a 7.5 h time 
span, producing a result showing that caffeine concentration on the fetal side increases until it 
reaches a steady‐state condition. In actual tests (with cells), caffeine concentration on the fetal side 
reached a steady‐state of 0.0033 mg mL−1, while in controlled tests it reached the steady‐state of 
0.0179 mg mL−1 in the interval between 6.5 and 7.5 h. On the maternal side, while initial 
concentrations fluctuated, they reached steady‐state within 7.5 h. The steady‐state value was 
0.1513 mg mL−1 between 6.5 and 7.5 h for the actual tests and 0.1307 mg mL−1 after 7 h for the 
controlled tests. This result clearly warrants further investigation on perfusing different caffeine 
concentrations to the maternal interface and the way they affect transfer rates. 
 
3.4 Experimental Section 
3.4.1. Cell Culture  
HUVECs (Lonza) were chosen to represent the cells at the fetal interface. The cells were 
cultured with endothelial basal medium (EBM, R&D Systems), supplemented with Endothelial 
cell growth supplement (R&D Systems) containing fetal bovine serum (FBS). BeWo (ATCC) was 
selected from a variety of trophoblast cell lines based on its adhesive properties, functionality, and 
phenotype.[36] BeWo was used to represent the cells at the maternal interface. The cells were 
cultured in Kaighn's Modification of Ham's F‐12K medium (Thermofisher), supplemented with 
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10% FBS (Thermofisher). Both cell lines were maintained in an incubator at 37 °C with 5% CO2 in 
air until they were 80–90% confluent. 
 
3.4.2. Design and Fabrication of the Chip 
The placenta‐on‐a‐chip device (Figure 3.5) consisted of two microchannels (height: 100 
microns; width: 400 microns) fabricated on two PDMS layers. An SU‐8 mold for the chip was 
created using standard soft lithography techniques. The silicon wafer mold was placed in a 15 cm 
diameter petri dish, and then a 10:1 w/w mixture of PDMS base and curing agent solution (Dow 
Corning) were introduced into the mold.[37-38] Once the PDMS had solidified at room temperature, 
it was cut and peeled away from the mold to separate it into upper and lower layers. To provide 
fluid access for each individual channel, inlet/outlet holes (1 mm diameter) were created using a 
biopsy punch. A 0.4 micron pore‐sized polyester track etched (PETE) membrane from the 
membrane inserts (Corning) was used to represent the barrier between fetal and maternal 
bloodstreams. The membrane covered the mid‐section of the lower channel before both layers 
were treated with plasma for 1 min, and the two PDMS layers were then aligned, attached, and left 
overnight to perfectly cure the bond. 1/16 ft diameter PEEK tubes (IDEX Health and Science) 
were then inserted into the inlets and outlets, attached to 0.062 × 0.125 in laboratory tubing (DOW 
Corning), then left overnight before use. After the layers were permanently bonded, the chip was 
UV‐sterilized for 20 min. Entactin–collagen IV–laminin (E–C–L, Millipore) solution was prepared 
from a diluted solution of E–C–L with a sterile serum‐free medium for each cell line up to a final 
concentration of 10 µg mL−1. Both sides of the membrane were initially coated with E–C–L 
solution, after which the chips were refrigerated overnight at 4 °C. Prior to cell seeding, the 
channels were washed twice with phosphate‐buffered saline (PBS) to remove excess E–C–L. 
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Figure 3.5.  The placenta‐on‐a‐chip consists of two layers of PDMS separated with a porous membrane and 
channel on each side. (a) Top and bottom layers with a porous membrane separating the channels before 
being attached. (b) Channels aligned and ready to be attached and the porous membrane placed in between 
the layers to separate the midsections of each channel (where two cell layers interact). (c) Cross‐sectional 
view of the channels. (d) Experimental concept that shows the maternal and fetal bloodstreams perfused 
through the channels (not to scale). 
 
3.4.3. Microfluidic Cell Seeding and Culturing on the Chip 
Once the HUVECs and BeWo cells reached 80–90% confluence, the cells were prepared 
for infusion. The density of the dissociated cells was adjusted to 5 × 106 cells mL−1. The HUVECs 
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were suspended in EGM medium, seeded into the lower channel, and incubated in an inverted 
position at 37 °C with 5% CO2 in air for 1 h to ensure reliable attachment to the membrane. 
Similarly, the BeWo cells suspended in F‐12K medium were introduced into the upper channel 
and incubated at the original position under similar conditions for 1 h. Once cell attachment was 
confirmed, the inlet of each channel was connected to 3 mL syringes (Becton, Dickinson and 
Company) filled with the respective growth media for each cell type seeded into the channels, after 
which the syringes were connected to a syringe pump driven at a constant volumetric flow rate of 
50 µL h−1. 
 
3.4.4. Observing Live Cells 
The HUVECs and BeWo cells were stained with CellTracker green and CellTracker orange 
fluorescent probes (Life Technologies), respectively. Dissociated cells were incubated with 
staining diluted serum‐free medium (final working concentration of 0.5–25 × 10−6 M) at 37 °C with 
5% CO2 for 45 min. 
 
3.4.5. Investigating the Barrier Permeability 
 
Three thousand megawatt fluorescein–dextran anionic probes (Invitrogen, ThermoFisher) 
were used to measure the barrier permeability function based on its transport between maternal 
and fetal channels. Fluorescein–dextran was first diluted in PBS to 100 mg mL−1 then brought to 
a final concentration of 0.1 mg mL−1 in F‐12K medium. F‐12K supplement for the maternal 
channel was replaced with dextran‐mixed F‐12K and perfused for 4 h. Flow from both maternal 
and fetal channels was collected each hour and the fluorescence intensity of the collected samples 
was analyzed using a microplate reader (BioTek Synergy 2). 
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3.4.6. Cell Characterization for Analyzing Intercellular Junctions 
After confirming proliferation of cells on membranes inside the channels for a minimum 
of 3 days, the channels were rinsed twice with 0.1 M PO4 buffer, after which the cells were fixed 
in 4% paraformaldehyde and incubated at room temperature for 20 min. The channels were then 
washed thrice with PBS at 7 min increments. The channels were subsequently incubated at room 
temperature in a blocking solution created using 5% normal donkey serum as the normal blocking 
serum (NBS, Jackson Immuno Research Labs), 0.4% bovine serum albumin (BSA), and 0.2% 
Triton X‐100 for 60 min. Following incubation, primary antibodies (E‐cadherin and VE‐cadherin 
[Cell Signaling Technologies] for BeWo and HUVECs, respectively) were diluted in previously 
prepared blocking serum and incubated in each channel overnight at 4 °C. After being washed in 
PBS 4 times, the channels were incubated for 90 min with secondary antibodies and DAPI solution 
diluted in the same blocking solution. The channels were then rinsed with PBS 4 times with 8 min 
intervals between each rinse. After carefully separating the membrane from the chip, it was 
mounted to a coverslip and imaged with an inverted microscope (Zeiss Axio Observer Z1). 
 
3.4.7. Analysis of Caffeine Transport 
An LC/MS analytical method was used to determine the caffeine concentrations, using an 
Agilent Technologies 1100 Series advanced high‐performance liquid chromatography (HPLC) 
tandem mass spectrometer equipped with a Poroshell 120 EC‐C18 2.7 µm 4.6 mm × 50 mm 
(Agilent) column (W.M. Keck Metabolomics Laboratory, Iowa State University), to detect 
caffeine levels.[39] This instrument is composed of a UV–vis capable diode array detector and an 
Agilent Technologies Mass Selective Trap SL detector equipped with an electrospray ion source. 
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To prepare the collected samples for runs, each sample was diluted at a ratio of 1:3 in 
methanol and vortexed for several seconds, after which the samples were centrifuged at 16 × g for 
5 min and 100 µL from each sample was transferred to separate vials. The mobile phase was a 
mixture of water (80% with 0.1% acetic acid) and acetonitrile (20% with 0.1% acetic acid). The 
mass analyzer operated with an ESI source in positive ion mode, and the flow rate and injection 
volume were 0.75 mL min−1 and 5 µL, respectively. The quantification for caffeine was 
determined by measuring the intensity of protonated molecular ions of caffeine at m/z 195. 
 
3.4.8. Caffeine Transport across the Placental Barrier 
Calibration curves were initially developed so that the correlation could be used to calculate 
the amount of caffeine transported from the maternal side to the fetal side. Different caffeine 
(Sigma Aldrich) concentrations ranging from 0.00001 to 0.25 mg mL−1 in EGM and from 0.05 to 
0.3 mg mL−1 in F‐12K were used to create calibration curves using the data collected via the LCMS 
method. Assuming that the area under the curve for the caffeine spike from chromatograms was 
proportional to the concentration of the caffeine in each medium, the two different graphs shown 
in Figure 3.3 c,d were used to represent the correlation between concentration of caffeine and area 
under the curve. A 0.25 mg mL−1 caffeine solution in F‐12K medium was then introduced into the 
maternal side. Following a 1 h perfusion period, samples were collected after every 30 min from 
both the maternal and fetal outlets, and each sample was analyzed using the LCMS method to 
identify the exact amount of caffeine transported across the placental barrier. 
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3.4.9. Quantification of Caffeine Concentrations and Transfer Rates 
Using Figure 3.3 c,d, the caffeine concentrations for both the maternal and fetal sides were 
quantified and used to study the percentage increase of caffeine concentration in the fetal 
compartment over a period of medium perfusion. Equation 3.3 was used to calculate the rate of 
caffeine transfer. 
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Abstract 
Opioid use disorder (OUD) has become a growing concern in the U.S. and has been a 
dominant presence among pregnant women, resulting in an unprecedented amount of prescription 
medications, particularly naltrexone (NTX), prescribed for pregnant women. Because of unknown 
potential harm that NTX can impose on the fetus and its premature brain, the needs for safety and 
regulation of NTX are still undetermined, so we fabricated a microfluidic device to mimic 
structural phenotypes and physiological characteristic of in vivo placental barrier to evaluate near-
transport simulations of NTX and its primary metabolite, 6β-naltrexol, across the human placental-
barrier-like membrane. Following transport analysis, epithelial and endothelial cell layers were 
evaluated for possible gene-expressions released by an in vivo human placenta during NTX and 
6β-naltrexol placental exposure. Mean NTX and 6β-naltrexol concentrations in co-culture devices 
exhibited ~4.21-fold and ~4.67-fold lower concentrations, respectively, compared to 
concentrations measured in acellular devices. When a 100 ng/mL of NTX and 6β-naltrexol (1:1) 
were administered to the maternal channel, the mean concentration for co-culture models exhibited 
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~2.5 % of NTX and ~2.2% of 6β-naltrexol of the initial maternal concentration. To prototype and 
simulate fetal-brain exposure, perfusate from a fetal channel was directed to cultured N27 cells 
that were then evaluated for gene-expression. Evidence of cell apoptosis was evaluated with 
staining for live/dead cells. Similar to procedures for an epithelial or an endothelial cell layer, 
gene-expression levels were assessed in N27 cells following 8-hour exposure, and the fabricated 
microfluidic device provided a most satisfactory platform for exploring NTX and 6β-naltrexol 
virtual transport across a simulated placental barrier environment.  
 
4.1. Introduction 
Opioids are composed of natural, artificial, and semisynthetic mediators that can play an 
essential role in relieving chronic and severe pain,[1] and the discomfort released by opioid intake 
has caused a demand upsurge for prescription opioids in the U.S., with more than 650 prescription 
opioids prescribed every day, particularly for back pain, injuries, and disorders in human body 
movement.[1-2] However, this is an alarming increase in opioid intake, with OUD usage more than 
quadrupling during the past decade.[3] For example, approximately 115 people fatally overdose 
from opioids every day, contributing to more than 66% of all drug overdoses,[4-5] unfortunately 
including much OUD use by pregnant women.[6] Over the past decade, published reports have 
shown that opioid mediators, especially heroin, are being used extensively among pregnant women 
in the U.S. (5.6 per 1000 live births).[3] In OUD cases, fetuses have faced incidents of neonatal 
abstinence syndrome (NAS), postnatal growth deficiency, neonatal mortality, neurobehavioral 
complications, and other similar impairments,[6] with studies reporting that over 85% of OUD 
instances among pregnant women were unintended, with an estimated 3.39 per 1000 births facing 
NAS.[3, 7-8] Given this alarming increase in OUD in pregnant women, prescription medications for 
treating opioid dependence have become more prominent.[3] 
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NTX, that exhibits little to no addictive qualities,[9-10] is a common form of medicine for 
treating opioid addiction. Its opioid antagonist functions by blocking µ-, к-, and δ-opioid receptors, 
thereby reducing opioid craving and drug-seeking behaviors.[3, 9] The medication operates by 
metabolizing cystolic dihydrodiol dehydrogenase into 6β-naltrexol through the liver. 6β-Naltrexol 
is a primary active metabolite of NTX that contributes 43% of its pharmacological response.[9, 11] 
While NTX is commonly used for OUD, two other opioid antagonists, methadone and 
buprenorphine, have been extensively used,[6] with both endorsed by the World Health 
Organization (WHO) as effective means for treating OUD, accompanied by office-based 
treatment, brief NAS development, and minimal drug exchanges.[3, 12-13] The same two opioid 
antagonists have been successful in treatment of cigarette and tobacco addiction[14] and cocaine[15] 
usage. Although buprenorphine and methadone have been successful in treating opioid-dependent 
patients, policy constraints have prevented some patient access to these medications,[6, 9] while 
NTX,  both affordable and accessible,[16] has been successful in treating alcoholism[11, 17] and 
heroin dependence [18], and has also  been effective in treating pruritus of uremia [19] and 
cholestasis[20], and in therapy related to obesity.[21] However, with limited data on safety and 
effectiveness of NTX during pregnancy, the NTX’s validity as an efficient means for treating OUD 
in pregnant women is still uncertain.[3] Currently, the Food and Drug Administration (FDA) is still 
undetermined as to whether NTX crosses the placenta, and it also cautions against use of NTX 
during lactation.[16, 22] In the latter case, the FDA labels NTX under the lactation subsection for 
prescription drug labeling, since medical practitioners know only of potential harm and side-effects 
NTX can impose during breastfeeding,[16] so an increase of in vivo and placebo-controlled NTX 
testing has occurred during the past decade.[3] 
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In vivo testing has been the most common form of testing for analyzing NTX concentration 
levels, with subjects that include mice[23-24], rats [25], and rhesus monkeys.[26] The downside of 
using these models for testing is that while their anatomies resemble those of human anatomy, 
their placental tissues lack the analogous cellular and tissue interactions.[27]  However, the in vivo 
studies have successfully analyzed NTX with respect to adverse levels of morphine in mice,[23] 
spinal cord transition states between different doses of NTX in rats,[25] and have also monitored 
behavioral changes in rhesus monkeys from NTX and 6β-naltrexol consumption.[26] In addition to 
in vivo as a form of NTX testing, placebo-controlled testing has also been utilized to some 
extent.[17, 20, 28] For the most part, these studies have recorded only psychological, and antipruritic 
reactions from NTX and did not directly evaluate opioid exposure in the placental tissue.[17, 20, 28] 
Fortunately, with the success of the organs-on-chips, specifically the placenta-on-a-chip, NTX and 
6β-naltrexol can be examined for its effects in a human placental barrier in vitro.  
The placenta-on-a-chip allows us to co-culture trophoblast and endothelial cells, two of the 
most prominent cell lines in the human placenta (Figure 4.1 (a)-(c)), and to monitor NTX and 6β-
naltrexol exposure on the micro-engineered barrier. Culturing the following cell lines allows us to 
replicate the physiology of an in vivo human placenta, providing us with similar natural and 
reoccurring reactions from NTX and 6β-naltrexol. Previous studies have proven the validity of 
using placenta-on-a-chip for assessing and replicating different drug transport analysis while 
mimicking physiological function of human placenta in vitro.[29-35] Through our most recent study, 
we analyzed caffeine transport across our fabricated microchip, and proved the model to be 
compatible with withstanding xenobiotic exposure.[35] Therefore, since placenta-on-a-chip has yet 
to be tested with opioid contact, our study provides the first appraisal examining NTX and 6β-
naltrexol on an organ-on-a-chip. 
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Figure 4.1. Structure of the human placenta and design of the placenta-on-a-chip device. (a) The placenta 
is an interim organ that develops only during pregnancy and connects the fetus to the uterine wall via an 
umbilical cord. (b) Cross-sectional schematic of the human placenta containing important structures called 
chorionic villi that occupy and demolish uterine decidua and absorb nutritive materials to support fetus 
maturation; their development is due to the rapid proliferation of trophoblasts. (c) Structure of the placental 
villi. Syncytiotrophoblast and endothelial cells in maternal and fetal interfaces, respectively, are separated 
by a basal lamina (a layer of extracellular matrix), at the end of gestational period. During the first trimester, 
the maternal interface consists of syncytiotrophoblast and cytotrophoblast cells. (d) – (f-f) Exploded, 
assembled, and cross-sectional views of the fabricated placenta-on-a-chip before microfluidic cell culture. 
This device, fabricated to resemble the human placental barrier in vitro, consists of two microchannel-
etched PDMS layers separated by a thin semipermeable membrane. (g) Cross-section of a placenta-on-a-
chip after microfluidic cell culture, with the endothelium in the fetal interface and the epithelium in the 
maternal interface are respectively represented by HUVEC and BeWo cell layers.  
This study’s intended purpose was to evaluate opioid transport in our placenta-on-a-chip 
model, and this stage of testing is made possible through the system and foundation of the placenta-
on-a-chip, microfluidic device.[32-35] Microfluidic devices provide us with the ability to culture and 
manage cellular and subcellular environments within our microchip, maintain fixed compositions 
of our cell lines, and replicate fluid movement in parallel layers.[27, 36-42] Our microfluidic device 
((Figure 4.1 (d)-(f-f)) was fabricated using standard lithography techniques.[43-46] To represent the 
human placenta’s endothelium and trophoblastic epithelium, human umbilical vein endothelial 
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cells (HUVECs) and trophoblasts cells (BeWo) were cultured accordingly. Once these cells had 
exhibited behavioral bonding and placental structure in vitro after cell seeding and culturing in 
their respective microchannels, we began exposing our microfluidic device with NTX and 6β-
naltrexol. Additionally, by transferring outflow from the fetal channel to cultured N27 embryonic-
dopamine cells (N27 cells), we presented a proof-of-concept for modeling NTX and 6β-naltrexol 
transport to a fetus brain across the placental barrier. We also used a quantitative polymerase chain 
reaction (qPCR) method to analyze gene-expression changes that ensue from post-exposure to 
NTX and 6β-naltrexol. This work provides a platform for both scientific and pharmaceutical 
communities to examine and extrapolate information regarding safety and potential side-effects 
caused by prescription opioid medication during pregnancy. More specifically, the knowledge 
gained should encourage other researchers to test and validate the short and long-term influences 
NTX imposes on the mother’s placental barrier and the fetus’s premature brain.  
 
4.2. Experimental Section 
 4.2.1. Cell Culture 
HUVECs and BeWo were chosen to present the cells at the fetal and maternal interfaces, 
respectively, as previously described.[35] BeWo cells (ATCC) were cultured in Kaighn’s 
Modification of Ham’s F-12K medium (Thermofisher), supplemented with growth factors and 
10% fetal bovine serum (FBS, Gibco). HUVECs (Lonza) were cultured in endothelial growth 
medium (EGM, R&D Systems). N27 embryonic-dopamine cell line was generously provided by 
Dr. Anumantha Kanthasamy at Iowa State University. N27 cells were cultured in RPMI 1640 
medium (Gibco), supplemented with 10% FBS, 2mM L-glutamine (Gibco), and 100 U/mL 
penicillin and streptomycin (Gibco). Cell lines were incubated at 37 0C with 5% CO2 in air until 
they were 80-90% confluent. After at least three passages, N27 cells were dissociated with 
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trypsin/EDTA (1X) (Cascade Biologics) and plated into individual wells of a 6-well plate at a 
density of 25 ×103 cells/well.  
 
 4.2.2. Design and Fabrication of the Chip 
The placenta-on-a-chip consists of two polydimethylsiloxane (PDMS) slabs, each with a 
microchannel constrained by the following dimensions: 100 µm (height) and 400 µm (width). The 
microfluidic device was fabricated using a silicon wafer SU-8 mold produced through standard 
soft lithography techniques. A mixture of PDMS base and curing agent solution (Dow Corning) at 
10:1 (w/w) was introduced into a SU-8 mold placed in a petri dish (15 cm in diameter), as 
previously described.[35] The PDMS was cut and removed from the mold as upper and lower layers 
after the PDMS had solidified at room temperature.  A biopsy punch was then used to produce 
inlet/outlet holes (1 mm in diameter) on the upper PDMS layer. A polyethylene terephthalate 
(PETE) membrane (0.4 µm pore size) as the barrier between two channels, taken from the 
membrane inserts (Corning®), was placed over the mid-section of the lower channel, after which 
both PDMS layers were plasma-treated, aligned, bonded together, and left overnight to completely 
cure the bond. The chip was UV-sterilized for 20 minutes following attachment of inlet/outlet 
tubing to provide fluid access to each channel, as described previously.[35]   
 
4.2.3. Microfluidic Cell Culture 
Following UV-sterilization, an Entactin-collagen IV-laminin (E-C-L, Millipore) solution 
(10 µg/mL in sterile serum-free medium) was coated across both faces of the PETE membrane 
through the channel inlets, and the chip then was refrigerated overnight at 40C. On the following 
day, phosphate-buffed saline (PBS) was perfused twice to remove and wash excess E-C-L from 
the microfluidic device’s channels, after which the microchip was prepared for microfluidic cell 
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culture. Before infusion, both cell lines were dissociated with trypsin/EDTA (1X) and cells were 
resuspended in full growth medium (EGM or F-12K medium). Initially, the HUVECs were 
introduced into the lower channel at a density of ~5 × 106 cells/mL, then incubated at an inverted 
position at 370C with 5% CO2 in air for 1 hour to ensure adherence of cells to the membrane. 
Similarly, the BeWo cells were seeded into the upper channel at a density of ~5 × 106 cells/mL, 
and after the cells had exhibited adhesion to the membrane, 3 mL syringes (Becton, Dickinson, 
and Company) filled with EGM and F-12K medium were connected to the inlets of the lower and 
upper channels, respectively. The syringes were then connected to a syringe pump operated at a 
flow rate of 50 μL/hour. 
 
4.2.4. Live Cell Staining 
The BeWo cells and HUVECs were initially stained with CellTracker orange and green 
(Life Technologies), respectively. Both cell lines were incubated at 370C with 5% CO2 for 45 
minutes with staining in a diluted serum-free medium before dissociation, conforming to the 
manufacturer’s recommended protocol. 
 
4.2.5. Immunohistochemistry  
Investigation of the epithelial and endothelial integrity was carried out after confirming 
proliferation of cells in the microchannels. Initially, cultures in the fetal and maternal channels 
were fixed in 4% paraformaldehyde at room temperature for 20 minutes then rinsed with PBS, 
after which the microchannels were incubated with a blocking buffer (0.4% bovine serum albumin 
(BSA), 0.2% Triton X-100, and 5% normal donkey serum (Jackson Immuno Research Labs)) for 
60 minutes at room temperature. After incubation, microchannels were incubated overnight at 40C 
with anti-vascular endothelial-cadherin (VE-cadherin) and anti-epithelial cadherin (E-cadherin) 
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(Cell Signaling Technologies) for HUVECs and BeWo cells, respectively (primary antibodies 
were diluted with blocking buffer). On the following day, the microchannels were rinsed with PBS 
followed by incubation with secondary antibodies and DAPI solution (diluted with blocking 
buffer) in the dark for 90 minutes. Finally, both microchannels were rinsed with PBS and the chip’s 
membrane was carefully separated from the microchip, mounted to a coverslip, and examined for 
immunostaining using an inverted fluorescence microscope (Zeiss Axio Observer Z1).  
 
4.2.6. Staining to Visualize Microvilli Formation  
After 72 hours of proliferation of cells in the channels, BeWo cells were stained for 
filamentous actin (F-actin) to visualize formation of microvilli. Following a PBS rinse, the 
maternal channel was fixed with 4% paraformaldehyde for 15 minutes, after which the cultures in 
the channel were rinsed with PBS and permeabilized with 0.5 % Triton X-100 for 10 minutes at 
room temperature. After another PBS rinse, cultures were stained with CF® 488A-conjugated 
phalloidin (Biotium) (5 µL of a 200 U/mL (in cell culture grade water) stock solution in 200 µL 
of PBS). Following a counterstain of cell nuclei with DAPI, cells were incubated for 20 minutes 
at room temperature, washed with PBS, then imaged with a Zeiss Axio Observer Z1 Microscope.  
 
4.2.7. Investigating the Barrier Permeability  
The barrier permeability function of the transport between the fetal and maternal 
microchannels was analyzed using 3000 MW fluorescein-dextran anionic probes (Invitrogen, 
ThermoFisher), as described previously.[35] The Fluorescein-dextran was initially diluted in PBS 
to 100 mg/mL, in conformance with the manufacturers’ recommended protocol, then the 
fluorescein-dextran solution was placed in F-12K medium and brought to a final concentration of 
0.1 mg/mL. The maternal channel’s F-12K supplement was then replaced and perfused with 
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dextran-mixed F-12K for 10 hours. At subsequent 2-hour intervals, the perfusate from both the 
fetal and maternal channels was collected and its fluorescence intensity quantified utilizing a 
microplate reader (BioTek Synergy 2). 
 
4.2.8. NTX and 6β-Naltrexol Transport Across the Placental Barrier  
NTX and 6β-naltrexol were generously provided by Dr. Wolfgang Sadee and Dr. John 
Oberdick of Ohio State University. NTX and 6β-naltrexol at 1:1 (w/w) were first diluted to 1 
mg/mL (in cell culture grade water) then diluted to a final concentration of 100 ng/mL (in F-12K 
medium). The medium supplement for the maternal channel was then substituted for the NTX/6β-
naltrexol-mixed F-12K medium and perfused for 1 hour to remove the NTX/6β-naltrexol-free F-
12K medium from the maternal channel. After 1 hour of equilibrium, perfusate was collected every 
30 minutes from the fetal channel and analyzed by liquid chromatography/mass spectrometry (LC-
MS), and the permeability between the fetal and maternal channels in the microfluidic device 
during NTX/6β-naltrexol perfusion was analyzed using dextran anionic probes. Fluorescein-
dextran was diluted in NTX/6β-naltrexol-mixed F-12K medium (to a final concentration of 0.1 
mg/mL) and perfused through the maternal channel, after which the outflow was sequentially 
collected at 2-hour intervals and its fluorescence intensity was evaluated using a microplate reader, 
as described above.  
 
4.2.9. LC-MS for Detection of NTX and 6β-Naltrexol  
An Agilent Technologies 6540 Ultra-High-Definition (UHD) Accurate-Mass Quadrupole 
Time-of-Flight (Q-TOF) LC-MS system equipped with an Agilent Technologies Eclipse C18 1.8 
µm 2.1 mm × 100 mm column (W. M. Keck Metabolomics Laboratory, Iowa State University) 
was used to perform analysis of NTX and 6β-naltrexol in collected outflow samples. The Agilent 
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system was equipped with a thermostatically-controlled dual-needle injector coupled to an Agilent 
Technologies 1290 Infinity Binary Ultra High-Pressure Liquid Chromatography (UHPLC) system. 
The samples were initially transferred into 300 µL conical volume inserts (Thermo Scientific) in 
2 mL Surestop vials (Thermo Scientific), loaded onto the Autosampler tray and kept at 40C during 
the Q-TOF measurement. A gradient of 1.2 mM ammonia formate (pH 3.5) in High Performance 
Liquid Chromatography (HPLC) grade water (buffer A) and 1.2 mM ammonia formate (pH 3.5) 
in a mixture of HPLC grade acetonitrile and methanol (1:2) (buffer B) was used for 
chromatographic separation. After a 0.2-minute holding time in 100% buffer A, the gradient had 
transitioned to 33.3% and 48% buffer B in 5.2 to 6.2 minutes, respectively. The composition was 
switched to 100% buffer B at 8 minutes, followed by a 1-minute hold before returning it to initial 
conditions by a 4-minute post-run. Electrospray ionization in positive mode was used to detect 
NTX and 6β-naltrexol as [M + H]+ ions (flow rate: 0.4 mL/minute, injection volume: and 10 µL). 
NTX and 6β-naltrexol were identified at m/z 342.17 and 344.18, respectively. Calibration 
standards were prepared as a diluted series of combined NTX and 6β-naltrexol at 1:1 (w/w) (first 
diluted in cell culture grade water then to a final concentration in F-12K medium) at the following 
concentrations: 0.1. 0.5, 1, 5, 12.5, and 25 ng/mL. Agilent Mass Hunter Quantitative Analysis 
B.07.00 software was utilized to quantify the detection of NTX and 6β-naltrexol. The calculated 
concentrations of NTX and 6β-naltrexol were adjusted to their final values based on relative 
volume of samples collected from the outflow of the fetal channel.[47-48]  
 
4.2.10. Midbrain-Derived Embryonic N27 Cell Exposure to NTX and 6β-Naltrexol  
After 5 days of culture, the N27 cells in the 6-well plates were prepared for exposure to 
NTX and 6β-naltrexol. Following the NTX/6β-naltrexol-mixed F-12K perfusion, outflow of the 
fetal channel was directed to N27 cell-cultured individual wells of a 6-well plate. The treatment 
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was performed for 8 hours after 1 hour of equilibrium phase, as described above. Three different 
experiment groups including two control conditions were used for data analysis under the 
following conditions: N27 cells cultured in RPMI 1640 medium and had no exposure to NTX and 
6β-naltrexol, N27 cells (in RPMI 1640 medium) exposed to the outflow from the fetal channel 
without NTX and 6β-naltrexol in system, and N27 cells (in  RPMI 1640 medium) treated with 
NTX and 6β-naltrexol through the outflow of the microfluidic channel, for 8 hours.  
 
4.2.11. Quantitative Polymerase Chain Reaction (qPCR) 
After exposure to NTX and 6β-naltrexol, HUVECs and BeWo cells from the microfluidic 
device or N27 cells from 6-well plates were quantified using the qPCR method. After treatment, 
control and experimental samples were trypsinized, pelleted, and frozen at -800C, then integrated 
into single-control and single-experimental sets before homogenization in TRIzol reagent 
(Invitrogen, ThermoFisher). Following homogenization, RNA isolation and reverse transcription 
were performed using the Absolutely RNA Miniprep kit (Stratagene) and cDNA synthesis system 
(Applied Biosystems), respectively. A Qiagen RT2 SYBR Green master mix with validated qPCR 
human primers (for HUVECs and BeWo cells) or mouse primers (for N27 cells) from Qiagen 
(Frederick) were used to determine relative magnitudes of gene-expression levels using qPCR. 
Human 18S rRNA or mouse 18S rRNA, the housekeeping genes, were used to normalize each 
sample, and melting curves and dissociation curves were constructed to verify the gathering of 
nonspecific amplicons-free peaks, as described in manufacturer’s recommended guidelines. The 
ΔΔCt method developed to utilize threshold cycle (Ct) values from housekeeping gene and 




4.2.12. Live/Dead Cell Assay 
After exposure to NTX and 6β-naltrexol, assessment of both live and dead cells on the N27 
cell line was performed with a combination of 10 µM CellTracker green and 4 µM Propidium 
Iodide (PI, Invitrogen, ThermoFisher) solutions. Each solution was diluted in serum-free medium, 
following the manufacturers’ recommended protocol. Live and dead cells were detected with green 
fluorescent protein (GFP) and red fluorescent protein (RFP), respectively, using an Inverted 
Microscope (Zeiss Axio Observer Z1). The numbers of live and dead cells were determined using 
ImageJ software.  
 
4.2.13. Statistical Analysis 
All experiments were repeated at least three times, with results reported as mean ± S.E.M. 
Data analysis was performed using a two-tailed Student’s t-test or one-way analysis of variance 
(ANOVA) using MATLAB (The MathWorks Inc.) or OriginPro (OriginLab Corp.), respectively.   
 
4.3. Results and Discussion 
4.3.1. Fabrication and Verification of Placental-Barrier-Like Semipermeable Membrane  
The co-cultured microfluidic device consisted of three layers (Figure 4.1 (g)) that replicate 
a human placenta in vitro, similar to that from a previous study.[35] The top layer, or maternal 
channel, was composed of BeWo cells that represent the trophoblastic epithelium of the human 
placenta. Beneath the top layer is a thin semipermeable membrane that imitates the human 
placental barrier, and adhered to the bottom of the porous membrane is the fetal channel, comprised 
of HUVECs, to recapitulate the endothelium of a human placenta. The combination of the three 
layers provides a microfluidic platform for reconstructing the human placental barrier in vitro to 
study NTX and 6β-naltrexol transport across the maternal-fetal interface. To validate that the  
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Figure 4.2. Following 24-30 hours of media perfusion under dynamic flow conditions, epithelial and 
endothelial cell layers were stained with CellTracker live cell staining. (a) BeWo cells were stained with 
CellTracker orange and scrutinized for red fluorescent protein (RFP). (b) HUVECs were stained with 
CellTracker green and analyzed for green fluorescent protein (GFP). (c) Fluorescent microscopic image 
showing epithelial cells (BeWo) stained with anti-E-cadherin and nuclei labeled with DAPI. E-cadherin is 
a crucial transmembrane protein to maintain cell-cell junctions in epithelial adherens junctions (AJs). (d) 
Fluorescent microscopic image displaying endothelial cells (HUVECs) stained with anti-VE-cadherin and 
nuclei labeled with DAPI. VE-cadherin is an essential endothelial-specific protein responsible for 
controlling endothelial permeability and maintaining cell-cell junction stabilization in AJs. (e) Formation 
of microvilli on the apical surface of the trophoblast was assessed by testing for the presence of filamentous 
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actin (F-actin) protein. (f) Placental barrier permeability was investigated using fluorescein-dextran 
transport across the epithelial-endothelial barrier. n = 3 independent experiments. Data represented as mean 
(± S.E.M.). Scale bars, 50 µm. Two-tailed Student’s t-test, ****, p < 0.0001. 
microarchitecture of the microfluidic device’s soluble microenvironments was represented 
accurately, cell characterization was performed within the chip. For example, to ensure that the 
entire surface of the maternal and fetal sides of the porous membrane in channels was covered 
with BeWo cells and HUVECs, both cell lines were seeded on their respective sides of the cellular 
matrix and maintained under dynamic flow conditions. After 24-30 hours of microfluidic cell 
culture, the cells labeled with CellTracker live cells staining (Figure 4.2 (a) and (b)) reflected a 
proliferation over time of cell populations across the porous membrane in the corresponding 
channels. The dynamic flow environment in both channels precisely resembled the blood 
circulation within the maternal and fetal interfaces of the human placenta.  
After cell proliferation across both microchannels within their corresponding sides of the 
ECM-coated membrane had been confirmed, after 48 hours of microfluidic cell culture under 
dynamic flow conditions, we verified the epithelial and endothelial integrity of the 
microengineered barrier. For investigation of epithelial integrity, because epithelial cell-cell 
junctions formed by cell surface protein have a prominent role in retaining epithelial integrity, E-
cadherin antibody was used to detect efficient cell-cell junctions in the epithelium.[51] E-cadherin, 
a transmembrane protein essential for maintaining cell-cell junctions in epithelial adherens 
junctions (AJs), reflects the stability and durability of cell-cell junctions in epithelium. As shown 
in Figure 4.2 (c), strong complexes of E-cadherin detected on the BeWo cells suggested existence 
of the epithelium cell-cell junctions throughout the membrane in the maternal compartment. 
Additionally, in a mature epithelium, high cadherin densities are formed within AJs,[52] and the  
uniform E-cadherin found within the epithelial cell layer suggests the presence of AJs in the 
maternal cell layer of the microfluidic device. VE-cadherin antibody was next used to examine the 
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endothelial integrity with respect to adopting AJs in endothelial cells. Interendothelial adhesive 
junctions play a crucial role in maintaining structural integrity and controlling permeability in 
endothelium,[53] and, importantly, VE-cadherin is considered an essential component of AJs to 
maintain endothelial permeability and cell-cell junction stabilization.[54] VE-cadherin was detected 
across the HUVECs, validating the existence of a distinct network of AJs on the endothelial cell 
layer. In addition, the immunofluorescence micrograph in Figure 4.2 (d) shows that this cell-
specific cadherin protein was homogeneously distributed throughout the endothelium, so the 
complexes displayed from the anti-E-cadherin in epithelium and the anti-VE-cadherin in 
endothelium confirmed the formation of cell-cell junctions in AJs and the epithelial and endothelial 
integrity of the placental barrier in vitro. 
Following the investigation of cell-cell interactions, the maternal channel was evaluated 
for microvilli formation, because the microvillus plasma membrane is involved in facilitating 
hormonal and immunological interaction between mother and fetus.[55] The highly-structured 
microvilli based in the intervillous space and surrounded by plasma membrane, are considered to 
be major placental structural components that facilitate materno-fetal transport of nutrients and 
metabolites through facilitated/simple diffusion, active-transport, phagocytosis, and 
pinocytosis.[56-57] As pregnancy proceeds, microvilli are also responsible for placental surface 
increase by their increase in number and density,[58] so the microvilli in the maternal surface of the 
syncytial trophoblast cell layer are considered another key characteristic of the human placenta in 
vivo when constructing a placental-barrier-like semipermeable membrane.  The microvilli herein 
were evaluated by the presence of F-actin protein, essential for cell stability and morphogenesis. 
As shown in Figure 4.2 (e), a dense layer of microvilli was observed on the fluorescence 
microscopy images, and variability this dense layer was detected along the apical surface of the 
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trophoblast cell layer, possibly attributed to differing fluid shear stresses caused by trophoblast 
cells forming a 3D structure inside the maternal channel, as previously described.[35] Previous 
studies for visualizing microvilli under static conditions have resulted in sparse microvillar 
surfaces.[29, 31, 33] In conjunction with such previous studies, microvilli visualized herein dynamic 
flow conditions have demonstrated elongated microvilli formation in our study.  
Once the surface of the trophoblast cell layer was evaluated for formation of microvilli in 
the maternal channel, placental barrier permeability was analyzed to investigate integrity of the 
placental barrier. The placental barrier function was assessed using 3000 MW fluorescein-dextran 
anionic probes as a permeability assay. Over a 10-hour period, perfusate from both channels was 
collected from acellular and co-culture devices and analyzed using calculated mean fluorescence 
intensities (MFIs). As shown in Figure 4.2 (f), MFIs of the fetal perfusate from acellular devices 
confirmed a significant passage of fluorescein-dextran (p < 0.0001) compared to those collected 
from the fetal compartment of co-culture devices. Results in Figure 4.2 (f) also revealed that in co-
culture devices, while a few molecules passed through the semipermeable membrane, over a 10-
hour period, the overall number of MFIs in the fetal compartment of co-culture devices were 
negligible compared to those in the perfusates collected from the maternal compartments of both 
acellular and co-culture devices.   
The structural phenotypes of the in vitro placental barrier were examined to determine the 
capability of co-culturing epithelial and endothelial cell layers, to verify the proliferation of the 
cells in each layer, to validate the epithelial and endothelial integrity, and to analyze barrier 
permeability. Formation of microvilli in the maternal surface was used as an important 
physiological characteristic in validating the placental barrier in vitro. Considering the ability of 
replicating structural phenotypes and physiological characteristics of an in vivo placental-barrier, 
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our placental-barrier-like membrane fabricated on a microfluidic device provides an ideal platform 
for modeling near-transport simulation of nutrients and metabolites of a human placental barrier.   
  
4.3.2. Analysis of NTX and 6β-Naltrexol Transport Across the Placental Barrier 
In this study, we investigated the possibility of mimicking NTX and its primary metabolite, 
6β-naltrexol transport, across our fabricated in vitro placental barrier. NTX is capable of blocking 
µ-, к-, and δ-opioid receptors, but its clinical effects are mainly administered by blocking the µ- 
opioid receptor.[59] NTX to 6β-naltrexol plasma levels were used at dilutions of 1: 10 and 1:1 for 
oral dosing and long-acting injection, respectively.[60] Previous studies have demonstrated that 
blood NTX of ~8 ng/mL has achieved and putrefied to a level of 1.1 ng/ mL within 24 hours after 
digesting one 50 mg tablet,[61] and ~2-10 ng/mL was identified as a clinically-relevant NTX plasma 
concentration during sustained NTX exposure from NTX implants.[62-63] While it is an oral NTX 
accomplice with weak compliance, e.g., for pregnant women with opioid dependence, long-acting 
injection of NTX provides a potential for using it as a probable medication.[64-65] Since this study 
was carried out to demonstrate the possibility of utilizing our placental barrier in a microfluidic 
device to study the transport of NTX and 6β-naltrexol across human placenta in vitro, we 
introduced a final concentration of 100 ng/mL NTX and 6β-naltrexol (1:1) to the maternal channel. 
A concentration of 100 ng/mL in this proof-of-concept was also used to receive a detectable level 
of NTX and 6β-naltrexol concentrations via LC-MS in perfusate collected from the fetal channel. 
 Initially, as a control condition, we administered NTX and 6β-naltrexol through an 
acellular device with no epithelial and endothelial cell layers. As shown in Figure 4.3 (a), fetal 
naltrexone concentrations calculated with compiling calibration standards (Figure 4.3 (b)) 
exhibited multiple fluctuation phases over a span of 8 hours. NTX concentrations exhibited sudden  
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Figure 4.3. (a) Naltrexone (NTX) concentrations in the fetal channel were quantified via liquid 
chromatography/mass spectrometry (LC-MS). (b) Calibration standards were plotted to perform NTX 
analysis. (c) 6β-Naltrexol concentrations in the fetal channel were assessed via LC-MS. (d) Diagram 
showing calibration standards prepared for quantification of 6β-naltrexol. Co-culture devices have both 
epithelial and endothelial cells. Acellular devices contain only the bare membrane with perfusion of media 
as a control condition. n = 3 independent experiments. Data represented as mean (± S.E.M.). 
drops at 4, 6.5, and 8 hours, and between t = 1 to t = 3.5 hours, t = 4 to t = 6 hours, and t = 6.5 to t 
= 7.5 hours, with similar patterns of increase observed during the study. This could be attributed 
to active transport of NTX back and forth between maternal-fetal interfaces. Overall, fetal 
concentration in acellular devices began to rise from an initial value (0.815 ± 0.044 ng/mL) and 
reached a maximum concentration of 16.882 ± 0.888 ng/mL at 7.5 hours. Conversely, fetal 
naltrexone concentrations in the perfusate collected from co-culture devices remained nearly stable 
without major significant fluctuations compared to concentrations in perfusates collected from 
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acellular devices. A slight drop in concentration was observed at 4 hours, and from t = 1 to t = 3.5 
hours and t = 4 to t = 8 hours, fetal NTX concentration maintained a mean of 1.491 ± 0.323 and 
3.176 ± 0.307 ng/mL, respectively. Additionally, before and after the slight drop, fetal NTX levels 
achieved a concentration of 2.712 ± 1.470 and 4.489 ± 0.834 ng/mL at 3.5 and 7.5 hours, 
respectively. Overall, the co-culture model maintained a ~4.21 times lower mean NTX 
concentration compared to that of the acellular model. 
 Similarly, fetal 6β-naltrexol concentrations were analyzed in perfusates collected in 
acellular and co-culture devices. As shown in Figure 4.3 (c), final 6β-naltrexol concentrations were 
quantified after interpolating with generated concentration standards (Figure 4.3 (d)). 
Correspondingly to fetal NTX concentrations in acellular devices, fetal 6β-naltrexol 
concentrations in acellular devices exhibited alike trend over a span of 8 hours. The concentrations 
of 6β-naltrexol in acellular devices exhibited rapid decrease at 4 and 6.5 hours, and, in contrast to 
NTX, this trend was also observed in fetal 6β-naltrexol concentrations in co-culture devices. For 
those hours, concentrations of 6.133 ± 3.009 and 12.497 ± 0.459 ng/mL for acellular devices and 
1.474 ± 0.715 and 2.542 ± 0.624 ng/mL for co-culture devices were detected, respectively. In 
comparison, mean fetal 6β-naltrexol concentrations from t = 1 to t = 3.5 hours, t = 4 to t = 6 hours, 
and t = 6.5 to t = 8 hours were observed as 6.707 ± 1.329, 12.998 ± 2.147, and 14.336 ± 1.487 
ng/mL for acellular devices and 1.267 ± 0.275, 2.259 ± 0.427, and 3.612 ± 0.428 ng/mL for co-
culture devices, respectively. The mean fetal 6β-naltrexol concentrations analyzed for perfusates 
collected from acellular devices exhibited a ~4.67-fold higher level compared to those in co-culture 
devices, for an interval of 8 hours. 
 Interestingly, in comparison with the initially-administered maternal NTX and 6β-naltrexol 
concentration (100 ng/mL), the mean fetal NTX and 6β-naltrexol concentrations evinced ~2.5% 
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and ~2.2% levels in devices in the presence of HUVECs and BeWo cells, respectively. Conversely, 
in the absence of HUVECs and BeWo cells, NTX and 6β-naltrexol concentrations were ~10.5% 
and ~10.3% levels with respect to the initial maternal concentrations. Uncommonly, the mean 
NTX and 6β-naltrexol concentrations evaluated for co-culture model began to rise after 6 hours 
and continued to increase until the end of the experiments, reaching higher mean concentrations 
compared to those from t = 1 to t = 6 hours (NTX: 1.936 ± 0.272; 6β-naltrexol: 1.718 ± 0.257). 
After 6 hours, concentrations sustained mean concentrations of 4.058 ± 0.288 and 3.612 ± 0.428 
ng/mL for NTX and 6β-naltrexol, respectively. We suspect that this may be due to a disturbance 
of barrier integrity of the epithelial and endothelial cell layers in our microfluidic device. If there 
was such a possible disruption in HUVEC and BeWo cell layers, a rise in concentration levels 
would be expected for both NTX and 6β-naltrexol because structural and physiological functions 
were not precisely represented during this scenario. Initially, to verify whether there was a 
disruption in epithelial and endothelial cell layers, after 8 hours, BeWo cells and HUVECs in 
microchannels were stained with CellTracker to visualize live cells, and as a control condition, the 
maternal channel in co-culture devices was perfused with F-12K medium with the absence of NTX 
and 6β-naltrexol. As shown in Figure 4.4 (a), for control conditions, the epithelial cell layer was 
not disrupted as seen for the co-culture devices with exposure to NTX and 6β-naltrexol ((Figure 
4.4 (b)), and similar observations were identified for the endothelial layer. HUVECs stained for 
live cells in the control ((Figure 4.4 (c)) seems to have a matured cell layer compared to the 
raptured cell layer in the co-culture devices with perfusing NTX and 6β-naltrexol ((Figure 4.4 (d)).  
Barrier permeability function was also evaluated to identify the time frame in which the 
disruption of cell layers occurs on the fabricated placental membrane. Fluorescein-dextran was 
mixed with NTX/6β-naltrexol diluted F-12K medium and perfused over a span of 8 hours.   
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Figure 4.4. Following NTX and 6β-naltrexol exposure, epithelial and endothelial cell layers were stained 
with CellTracker live-cell staining. Control and experimental conditions represent co-culture devices 
perfused with and without NTX/6β-naltrexol in the maternal flow, respectively. BeWo cells and HUVECs 
were stained with CellTracker orange and green, respectively. (a) BeWo cell layer under control conditions. 
(b) BeWo cell layer under experimental conditions. (c) HUVEC cell layer under control conditions. (d) 
HUVEC cell layer under experimental conditions. (e) Transport analysis of fluorescein-dextran across 
acellular and co-culture devices to evaluate barrier permeability during the NTX/6β-naltrexol transport 
study. n = 3 independent experiments. Data represented as mean (± S.E.M.). Scale bars, 50 µm. Two-tailed 
Student’s t-test, *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
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In contrast to live-cell analysis during NTX/6β-naltrexol exposure, control and experimental 
studies were performed in acellular and co-culture devices, respectively. No significant differences 
were observed, and virtually-constant levels of MFIs were displayed in perfusates collected from 
co-culture devices during the first six hours. The MFIs evaluated from t = 6 to t = 8 hours in co-
culture devices implied a statistical-significant increase (p < 0.001) compared to MFI at t = 6 hours. 
In comparison with MFI levels measured over 6 hours in co-culture devices, the levels showed 
~4.5 times greater values in perfusates evaluated from t = 6 to t = 8 hours. Interestingly, no 
significant differences were observed within MFIs of perfusates collected from acellular devices 
at 2-hour intervals for 8 hours. In addition, the MFIs in co-culture devices always remained lower 
than those evaluated in perfusates collected from acellular devices. This not only verified that the 
disruption visualized in microscopic imaging of HUVEC and BeWo cell layers occurred between 
t = 6 to t = 8 hours, but also confirmed that, after 6 hours of NTX/6β-naltrexol exposure, the in 
vitro placental barrier became profoundly permeable to fluorescein-dextran. This placental barrier 
alteration existing after 6 hours of NTX and 6β-naltrexol perfusion also supported the possibility 
of becoming eminently permeable to aforesaid drugs. Such a rupture of the in vitro placental barrier 
could be attributed to cell apoptosis due to effects of NTX and 6β-naltrexol on epithelial and 
endothelial cell layers.  
 
4.3.3. Genetic Analysis of the Placental Barrier Following Post-NTX/6β-Naltrexol Exposure 
 In this phase of the study, we evaluated possible genetic changes that the placental barrier 
undergoes following post-NTX and -6β-naltrexol exposure. Following an 8-hour perfusion of 
NTX/6β-naltrexol through the maternal channel, HUVECs and BeWo cells were dissociated and 
quantified using the qPCR method. A previous study reported that low-dose naltrexone (LDN) 
exhibited a reduced plasma concentration of interleukin (IL)-6 and tumor necrosis factor (TNF)-
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α.[66] TNF-α is considered a proinflammatory cytokine that worsens disease,[67] and IL-1α is 
another proinflammatory cytokine that binds IL-1 receptor.[68] Conversely, IL-6 not only performs 
as a proinflammatory cytokine, but also an anti-inflammatory myokine and a cytokine involved in 
responding to inflammation and infection.[69-70] IL-8 is another cytokine responsible for activating 
neutrophils in inflammatory regions.[71] These properties were evaluated with IL-1α, IL-6, and 
TNF-α for the HUVEC layer and IL-1α, IL-6, and IL-8 for the BeWo cell layer. 
Figure 4.5. Gene-expression analysis of epithelial and endothelial cells following NTX and 6β-naltrexol 
exposure, via qPCR method. Control conditions consisted of cells in a co-culture device with perfusing 
NTX- and 6β-naltrexol-free media through the maternal channel. Expression levels were reported as a fold 
change in gene-expressions analogous to that of human 18S rRNA, the housekeeping gene. (a) BeWo cells 
from maternal side were assessed for IL-1α, IL-6, and TNF-α genes. (b) HUVECs from the fetal side were 
evaluated for IL-1α, IL-6, and IL-8 genes. n = 3 independent experiments. Data represented as mean (± 
S.E.M.). Two-tailed Student’s t-test, *, p < 0.01. 
As shown in Figure 4.5 (a), proinflammatory cytokines, IL-1α and IL-6, implied lower fold 
changes in gene-expression levels when exposed to NTX and 6β-naltrexol compared to levels 
reported under control conditions. Interestingly, only IL-1α exhibited a significant difference (p < 
0.01) even though IL-6 also exhibited a decrease in fold change. TNF-α gene-expression revealed 
an increase in fold change levels, but no significant difference was detected. Intriguingly, when 
exposed to NTX and 6β-naltrexol, IL-1α and IL-6 fold change levels in HUVECs (Figure 4.5 (b)) 
exhibited completely different tendencies compared to fold change levels achieved in BeWo cells. 
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When evaluated for IL-1α and IL-6 in HUVECs, fold change displayed higher levels with no 
significant increase than those measured under control conditions. This change in fold change 
patterns could be attributed to epithelial and endothelial cell apoptosis during NTX/6β-naltrexol 
exposure. IL-8, a cytokine responsible for activating neutrophils in inflammatory regions, and 
evaluated in the endothelial cell layer, exhibited a decrease in fold change compare to that under 
control conditions. Since no significant difference was observed, IL-8 presented the possibility of 
achieving inflammatory-free conditions in fetal interfaces during an NTX/6β-naltrexol exposure. 
Due to the lack of availability of gene-expression analysis performed on the maternal and fetal 
interfaces during an NTX/6β-naltrexol exposure, further investigation is recommended to validate 
these results before comparing them to genetic analysis of an in vivo human placental barrier. 
 
4.3.4. N27 Embryonic-Dopamine Cell Line Exposed to NTX and 6β-Naltrexol  
In the next phase of the study, we proposed a possible concept for simulating effects on 
fetus brain cells from maternally-administered NTX and 6β-naltrexol to the placental barrier, 
because a previous study on pregnant mice reported that 6β-naltrexol enters the fetal brain at 
greater levels after promptly crossing the placental barrier.[8] In the previous phase of the study, 
we evaluated and quantified that both 6β-naltrexol, the primary metabolite of NTX, and the parent 
drug are capable of entering the fetal compartment. Even though this claim requires further study 
for validation, we speculated that, it is also possible for NTX to reach the fetus brain because NTX 
was found in the fetal compartment within the course of this study.  
 Initially, N27 cells, plated and cultured for 5 days, were exposed to NTX and 6β-naltrexol 
by simply directing the outflow of the fetal channel, and two control condition measurements were 
also used to compare the results obtained from N27 cells exposed to NTX and 6β-naltrexol. For  
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Figure 4.6. The outflow from the fetal channel was directed toward N27 cells cultured in 6-well plates and 
a live/dead assay was performed on the cells after 8 hours of continuous exposure to the following 
conditions: (a) Cells were maintained in RPMI 1640 medium with no exposure to outflow from the fetal 
channel. (b) Cells (in RPMI 1640 medium) were exposed to the fetal-channel outflow from the co-culture 
devices that perfused NTX- and 6β-naltrexol-free medium through the maternal channel (c) Cells (in RPMI 
1640 medium) were exposed to NTX and 6β-naltrexol through the fetal-channel outflow from co-culture 
devices. Live and dead cells indicated in green and red, respectively. (d) N27 cells under same conditions 
as above quantified to examine cell viability. Data were calculated from 3-4 images. (e) Gene-expression 
analysis on N27 cells subjected to conditions (a), (b), and (c). The mouse 18S rRNA, the housekeeping 
gene, was referenced to report gene-expression levels as a fold change. n = 3 independent experiments. 
Data represented as mean (± S.E.M.). Scale bars, 50 µm. One-way ANOVA, *, p < 0.05; **, p < 0.01; ***, 
p < 0.001; ****, p < 0.0001. 
the first control, N27 cells were maintained in RMPI-1640 medium without introducing outside 
conditions. The second control condition was to expose N27 cells to outflow from a fetal channel 
of co-culture devices operated without perfusing NTX or 6β-naltrexol, mainly to verify whether 
any significant differences can be observed due to the EGM from the fetal compartment because 
perfusate from the fetal channel contains EGM. Following an 8-hour transfer of perfusate to N27 
cells cultured in 6-well plates, cells were stained with a live/dead cell assay. As indicated in Figure 
4.6 (a) and (b), fluorescent images displayed only minor cell death under both control conditions, 
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while live/dead cell assays identified a large amount of cell death on the cell layer (Figure 4.6 (c)) 
exposed to the fetal channel from co-culture devices perfusing NTX and 6β-naltrexol. To quantify 
cell viability, fluorescent images were analyzed by counting live and dead cells. Cell viability 
(Figure 4.6 (d)) exhibited no significant difference (p > 0.05) for both control studies, verifying 
minimal effects against cell apoptosis after N27 cells exposed to EGM. In addition, an 
experimental study with N27 cells exposed to NTX and 6β-naltrexol showed a significant decrease 
in cell viability compared to cell viability found in both control studies (p < 0.001).  
 We next evaluated N27 cells for genetic changes following post-exposure to NTX and 6β-
naltrexol. The most important segment of this study phase is to determine possible, genetically-
defined aftereffects the fetal brain cells exhibit following a post-NTX and -6β-naltrexol exposure 
through a placental barrier in vitro. It has been reported that IL-6 and IL-1β expression levels have 
produced increases in plasma levels of fetal brains,[72] and acute inflammatory insult to a 
developing brain from IL-6 gene-expression,[73] and the possibility of TNF-α reducing embryonic 
development of the brain have also been reported.[74] Sphingosine kinase (sphk)1 enzyme is 
associated with increasing survival and proliferation of cells,[75] and sphk1 exhibits standard 
physiological functions in developing brain cells.[76] As indicated in Figure 4.6 (e), N27 cells 
exposed to NTX and 6β-naltrexol exhibited significantly higher fold change levels in IL-6 
compared to those under both control conditions, while the control conditions exhibited a 
significant difference (p < 0.05) in fold change levels for IL-6 gene-expression. Fold change levels 
revealed lower expression levels of IL-1β in N27 cells exposed to EGM and NTX/6β-naltrexol 
compared to levels in N27 cells maintained in RPMI-1640, but no significant differences were 
observed. Interestingly, sphk1 gene-expressed fold change levels measured in N27 cells in RPMI-
1640 and N27 cells exposed to NTX and 6β-naltrexol remained virtually-constant while the levels 
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for cells exposed to EGM showed a significantly higher fold change values compared to cells in 
RMPI-1640 and exposed to NTX and 6β-naltrexol (for both, p < 0.0001). This could be attributed 
to rapid cell growth in N27 cells when exposed to EGM, because extra growth factors in EGM 
could be promoting cell growth. While cells exposed to NTX and 6β-naltrexol were also exposed 
to EGM, we suspect that NTX and 6β-naltrexol exposure resulted in more effects than EGM 
exposure. Conversely, TNF-α gene-expression exhibited significantly lower fold change values in 
N27 cells exposed to EGM than in N27 cells exposed to NTX and its primary metabolite, and 
EGM. Further studies are warranted to validate these results achieved from genetic analysis of N27 
cells following post-exposure to NTX and 6β-naltrexol. This preliminary study was conducted to 
demonstrate the possibility of utilizing placenta-on-a-chip not only for investigating placental drug 
transport, but also for post-transport studies to different organs in a fetus, because drugs expected 
to be transported to other organs in a fetus when crossed the placental barrier.  
 
4.4. Conclusions 
In our study, we fabricated a human placental barrier in vitro, allowing us to investigate 
NTX and 6β-naltrexol transport across our micro-engineered barrier. Our multi-layered placenta-
on-a-chip design consisted of a maternal and fetal channel and a semipermeable membrane, with 
the maternal and fetal channels containing co-cultured trophoblast and endothelial cell lines, 
respectively. Both cell lines adhered to the opposite surfaces of the semipermeable membrane, 
confirming the placental barrier’s practical behavior. This multilayered placenta-on-a-chip 
allowed us to replicate the maternal-fetal interfaces of the human placenta and flow of the dynamic 
environment in the maternal and fetal bloodstreams in vitro. Initially, in vitro placental barrier was 
evaluated for structural phenotypes and physiological characteristics of a human placenta. 
Following the barrier verification, 100 ng/mL of NTX and 6β-naltrexol was introduced to the 
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maternal channel and perfused for 8 hours, and mean fetal NTX and 6β-naltrexol concentrations 
over this interval were recorded as 2.503 ± 0.255 and 2.223 ± 0.2515 ng/mL, respectively, for co-
culture devices. The epithelial cell layer after NTX and 6β-naltrexol exposure was evaluated for 
IL-1α, IL-6, and TNFα and endothelial cell layer was examined for IL-1α, IL-6, and IL-8 genes. 
During the next phase of the study, perfusate for the fetal channel was directed to investigate 
embryonic brain cells exposed to NTX and 6β-naltrexol. Following cell viability evaluation, cells 
were observed for IL-6, IL-1β, sphk1, and TNFα gene-expressions. With enhanced detection 
through LC-MS, this proof-of-concept can be used to analyze the transport of ~2-10 ng/mL 
(clinically-relevant plasma concentration for NTX) of NTX and 6β-naltrexol and its effects on a 
fetus and its premature brain. 
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CHAPTER 5.    GENERAL CONCLUSIONS 
The chapters in this dissertation provide proof-of-concept with respect to investigating 
transport of caffeine, naltrexone (NTX), and 6β-naltrexol, the major metabolite of NTX, across 
the placental barrier in vitro. In each studies, a single concentration of caffeine, NTX, or 6β-
naltrexol was used to quantify the fetal concentrations. To further investigate caffeine transport 
and identify a safe dosage of caffeine consumption during pregnancy, multiple maternal caffeine 
concentrations should be investigated. Similarly, multiple NTX and 6β-naltrexol concentrations 
should also be analyzed to more precisely determine how different dosages of NTX consumed by 
a mother could affect the fetus. Additionally, even though gene-expression analysis was performed 
on both endothelial and epithelial cell layers to identify genetic changes occurring post-NTX/6β-
naltrexol exposure, further long-term studies must be performed to confirm whether those results 
validate the reported findings. Although cancer-derived trophoblast cells (BeWo) and human 
umbilical vein endothelial cells (HUVECs) were used to represent the epithelium in the maternal 
interface and the endothelium in the fetal interface, respectively, there have been concerns about 
the accuracy of this microfluidic device’s maternal-fetal interface. To improve the physiological 
characteristics of the maternal-fetal interface in vitro, the current co-culture cell model should be 
replaced with a co-culture of primary villous trophoblast cells and human primary placental villous 
endothelial cells (HPVECs).[1]   
 In addition to studies presented in this dissertation, further drug-transport analysis and 
structural phenotype examination can be performed using with either the current placenta-on-a-
chip microfluidic platform or a slightly-modified system. Over the course of a pregnancy, the 
placenta goes through numerous structural changes that can affect the transport of oxygen, 
nutrients, xenobiotics, and pharmaceutical drugs, one change being an increase in villous surface 
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area, and by the third trimester the cytotrophoblast cell layer disappears and decreases the 
thickness of the placental membrane.[2] These structural changes allow the placental barrier to 
become more permeable to nutrients and drugs and enhance the passive diffusion transport 
mechanism. Conversely, during non-ideal situations such as infective conditions, the thickness of 
the placental membrane will increase and become less permeable by both drugs and nutrients due 
to a reduced passive diffusion transport mechanism.  
In addition to effects of such structural changes on the placental membrane, passive 
diffusion across the placenta is also dependent on a drug’s physiochemical properties, such as 
molecular weight, lipid solubility, degree of ionization, and protein binding,[2] and these properties 
can be effectively used when modeling drug-transport studies with the placenta-on-a-chip device. 
Along with passive transport analysis, since drugs are often transported by active transport and 
facilitated diffusion mechanisms, if facilitated diffusion studies are simulated in the placenta-on-
a-chip device, this will not only support verification of the respective transport mechanisms, but 
also will verify the potential of the in vitro model to mimic transporter physiology in the human 
placenta, because facilitated diffusion requires a carrier substance for transfer to occur. There have 
been previous investigations of glucose transport across the placenta, and further studies should 
be performed to simulate metabolic transfer of, for example, amino acid, fatty acid, electrolytes, 
vitamins, and water. Taken together, if oxygen supply to the fetus and carbon dioxide removal 
from the fetus across the placenta are modeled using the placenta-on-a-chip device, this suggests 
a possibility that similar investigation of non-ideal conditions will eliminate the need for some 
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